IQVIA (IQV) 10-Q 4 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	Apr. 30, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Trading Symbol	IQV
Entity Registrant Name	IQVIA Holdings Inc.
Entity Central Index Key	1,478,242
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		207,684,876

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Revenues	$ 2,563	$ 2,360
Costs of revenue, exclusive of depreciation and amortization	1,652	1,526
Selling, general and administrative expenses	420	381
Depreciation and amortization	282	232
Restructuring costs	26	19
Income from operations	183	202
Interest income	(2)	(2)
Interest expense	96	75
Loss on extinguishment of debt		3
Other expense (income), net	4	(1)
Income before income taxes and equity in earnings (losses) of unconsolidated affiliates	85	127
Income tax expense	19	24
Income before equity in earnings (losses) of unconsolidated affiliates	66	103
Equity in earnings (losses) of unconsolidated affiliates	7	(1)
Net income	73	102
Net income attributable to non-controlling interests	(4)	(2)
Net income attributable to IQVIA Holdings Inc.	$ 69	$ 100
Earnings per share attributable to common stockholders:
Basic	$ 0.33	$ 0.43
Diluted	$ 0.32	$ 0.43
Weighted average common shares outstanding:
Basic	207.5	230.1
Diluted	212	234.9

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 73	$ 102
Comprehensive income adjustments:
Unrealized gains on derivative instruments, net of income tax expense of $— and $1	1	1
Foreign currency translation, net of income tax benefit of ($40) and ($1)	207	122
Reclassification adjustments:
Losses on derivative instruments included in net income, net of income tax expense of $1 and $—	1	2
Comprehensive income	282	227
Comprehensive income attributable to non-controlling interests	(8)	(2)
Comprehensive income attributable to IQVIA Holdings Inc.	$ 274	$ 225

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Statement Of Income And Comprehensive Income [Abstract]
Unrealized gains on derivative instruments, income taxes		$ 1
Foreign currency translation, income taxes	$ (40)	$ (1)
Losses on derivative instruments included in net income, income taxes	$ 1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 960	$ 959
Trade accounts receivable and unbilled services, net	2,250	2,097
Prepaid expenses	148	146
Income taxes receivable	45	47
Investments in debt, equity and other securities	47	46
Other current assets and receivables	274	259
Total current assets	3,724	3,554
Property and equipment, net	432	440
Investments in debt, equity and other securities	28	8
Investments in unconsolidated affiliates	73	70
Goodwill	12,041	11,850
Other identifiable intangibles, net	6,580	6,591
Deferred income taxes	113	109
Deposits and other assets	244	235
Total assets	23,235	22,857
Current liabilities:
Accounts payable and accrued expenses	2,045	1,986
Unearned income	934	985
Income taxes payable	106	72
Current portion of long-term debt	104	103
Other current liabilities	10	10
Total current liabilities	3,199	3,156
Long-term debt	10,342	10,122
Deferred income taxes	828	895
Other liabilities	413	440
Total liabilities	14,782	14,613
Commitments and contingencies
Stockholders’ equity:
Common stock and additional paid-in capital, 400.0 shares authorized at March 31, 2018 and December 31, 2017, $0.01 par value, 250.0 and 249.5 shares issued at March 31, 2018 and December 31, 2017, respectively	10,797	10,782
Retained earnings	605	538
Treasury stock, at cost, 42.3 and 41.4 shares at March 31, 2018 and December 31, 2017, respectively	(3,460)	(3,374)
Accumulated other comprehensive income	254	49
Equity attributable to IQVIA Holdings Inc.’s stockholders	8,196	7,995
Non-controlling interests	257	249
Total stockholders’ equity	8,453	8,244
Total liabilities and stockholders’ equity	$ 23,235	$ 22,857

CONDENSED CONSOLIDATED BALANCE6

CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited) (Parenthetical) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Statement Of Financial Position [Abstract]
Common stock, shares authorized	400,000,000	400,000,000
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares issued	250,000,000	249,500,000
Treasury stock, shares	42,300,000	41,400,000

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Operating activities:
Net income	$ 73	$ 102
Adjustments to reconcile net income to cash provided by operating activities:
Depreciation and amortization	282	232
Amortization of debt issuance costs and discount	3	2
Amortization of accumulated other comprehensive loss on terminated interest rate swaps		3
Stock-based compensation	21	26
(Earnings) loss from unconsolidated affiliates	(6)	11
Benefit from deferred income taxes	(26)	(52)
Changes in operating assets and liabilities:
Change in accounts receivable, unbilled services and unearned income	(178)	(81)
Change in other operating assets and liabilities	13	(187)
Net cash provided by operating activities	182	56
Investing activities:
Acquisition of property, equipment and software	(88)	(78)
Acquisition of businesses, net of cash acquired	(20)	(150)
Purchase of trading securities	(1)	(1)
Investments in unconsolidated affiliates, net of payments received	4	(1)
Other	(15)	(10)
Net cash used in investing activities	(120)	(240)
Financing activities:
Proceeds from issuance of debt		3,998
Payment of debt issuance costs		(18)
Repayment of debt and principal payments on capital lease obligations	(26)	(2,491)
Proceeds from revolving credit facility	405	490
Repayment of revolving credit facility	(300)	(865)
(Payments) proceeds related to employee stock purchase and option plans	(11)	29
Repurchase of common stock	(95)	(1,316)
Distributions to non-controlling interest		(3)
Contingent consideration and deferred purchase price payments	(14)
Net cash used in financing activities	(41)	(176)
Effect of foreign currency exchange rate changes on cash	(20)	24
Increase (decrease) in cash and cash equivalents	1	(336)
Cash and cash equivalents at beginning of period	959	1,198
Cash and cash equivalents at end of period	$ 960	$ 862

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	1. Summary of Significant Accounting Policies The Company With more than 55,000 employees, IQVIA Holdings Inc. (together with its subsidiaries, the “Company” or “IQVIA”) conducts business in more than 100 countries. IQVIA is a leading global provider of advanced analytics, technology solutions, and contract research services to the life sciences industry. Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017. Income Taxes Income tax expense includes United States (“U.S”) federal, state and international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the same year. The income tax effects of these differences are reported as deferred income taxes. Valuation allowances are provided to reduce the related deferred income tax assets to an amount which will, more likely than not, be realized. As a result of the Tax Cuts and Jobs Act (the “Tax Act”) enacted on December 22, 2017, the Company no longer considers the undistributed earnings of its foreign subsidiaries to be indefinitely reinvested and will record deferred income taxes on these earnings, as applicable. The Company has provisionally recorded their U.S. deferred taxes based on the Federal corporate income tax rate of 21%. The Company is continuing to analyze aspects of the Tax Act and, therefore, has not finalized its accounting policy with respect to whether to (1) recognize deferred taxes for basis differences expected to reverse as Global Low Taxed Intangible Income (“GILTI”) or (2) account for GILTI as period costs if and when incurred. The Company has not recognized any deferred tax impacts related to GILTI or the Base Erosion Anti Abuse Tax (“BEAT”) on a provisional basis. Interest and penalties related to unrecognized income tax benefits are recognized as a component of income tax expense. Revenue Recognition The Company’s arrangements are primarily service contracts that range in duration from a few months to several years. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those goods or services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. Cash payments made to customers as incentives to induce the customers to enter into service agreements with the Company are amortized as a reduction of revenue over the period the services are performed. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. The Company derives the majority of its revenues in the Commercial Solutions segment from various information and technology service offerings. Information offerings (primarily under fixed-price contracts) typically include multiple performance obligations including an ongoing subscription-based deliverable for which revenue is recognized ratably as earned over the contract period, and/or a one-time deliverable of data offerings for which revenue is recognized upon delivery. The customer is able to benefit from the provision of data as it is received. The Company’s subscription arrangements typically have terms ranging from one to three years and are generally non-cancelable and do not contain refund-type provisions. Technology services offerings may contain multiple performance obligations consisting of a mix of small and large-scale services and consulting projects, multi-year outsourcing contracts and Software-as-a-Service (“SaaS”) arrangements. These arrangements typically have terms ranging from several weeks to three years, with a majority having terms of one year or less. For arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations based on their relative standalone selling prices. For these contracts, the standalone selling prices are based on the Company’s normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics and geographic location. Revenues for services engagements where the transfer of control occurs ratably over time are recognized on a straight-line basis over the term of the arrangement. Revenues from time and material contracts are recognized based on hours as the services are provided. Revenues from fixed price ad hoc services and consulting contracts are recognized over the contract term based on the ratio of the number of hours incurred for services provided during the period compared to the total estimated hours to be incurred over the entire arrangement (hours-based). Technology services offerings meet the over time criterion, as another party would not need to substantially re-perform the work already completed to satisfy the remaining obligations if the services were migrated to another party. The majority of the Company’s contracts within the Research & Development Solutions segment are service contracts for clinical research that represent a single performance obligation. The Company provides a significant integration service resulting in a combined output, which is clinical trial data that meets the relevant regulatory standards and can be used by the customer to progress to the next phase of a clinical trial or solicit approval of a treatment by the applicable regulatory body. The performance obligation is satisfied over time as the output is captured in data and documentation that is available for the customer to consume over the course of the arrangement and furthers progress of the clinical trial. The Company recognizes revenue over time using a cost-based based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Progress on the performance obligation is measured by the proportion of actual costs incurred to the total costs expected to complete the contract. Costs included in the measure of progress include direct labor and third-party costs (such as payments to investigators and travel expenses for the Company’s clinical monitors). This cost-based method of revenue recognition requires the Company to make estimates of costs to complete its projects on an ongoing basis. Significant judgment is required to evaluate assumptions related to these estimates. The effect of revisions to estimates related to the transaction price or costs to complete a project are recorded in the period in which the estimate is revised. Most contracts may be terminated upon 30 to 90 days notice by the customer; however, in the event of termination, a substantive termination penalty requires payment for services rendered through the date of termination, as well as for subsequent services rendered to close out the contract. The Company derives the majority of its revenues in its Integrated Engagement Services segment by providing contract sales and market access professionals to customers within the biopharmaceutical industry on a fee-for-service basis. Some of the Company’s Integrated Engagement Services contracts contain multiple performance obligations with distinct promises including recruiting, sales force automation and deployment of sales representatives. The nature of the terms of these performance obligations will vary based on the customized needs of the customer. For contracts that have multiple performance obligations, the standalone selling prices of the Company’s performance obligations are not directly observable since they are rarely sold standalone. Therefore, the Company estimates the standalone selling prices using an expected cost plus a margin approach under which expected costs of satisfying a performance obligation are forecasted and added to an appropriate margin for that distinct good or service. The Company utilizes a single measure of progress for each performance obligation to recognize revenue, which includes deployment of sales representatives based on employee days worked; recruiting based on candidates recruited; sales force automation set-up based on hours worked; and sales force automation hosting and maintenance based on usage. These services meet the over time criterion as the customer consumes the benefit as activities are performed and another party would not need to substantially re-perform the work already completed to satisfy the remaining obligations if the services were migrated to another party. Variable Consideration In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as performance incentives (including royalty payments or penalty clauses that can either increase or decrease the transaction price). Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company. Reimbursed Expenses The Company includes reimbursed expenses in revenues and costs of revenue as the Company is primarily responsible for fulfilling the promise to provide the specified service, including the integration of the related services into a combined output to the customer, which are inseparable from the integrated service. These costs include such items as payments to investigators and travel expenses for the Company’s clinical monitors and sales representatives, over which the Company has discretion in establishing prices. The Company controls the good or service and has inventory risk on contractually reimbursable expenses, as sometimes the Company is unable to obtain reimbursement from the customer for costs incurred. Change Orders Changes in the scope of work are common, especially under long-term contracts, and generally result in a change in transaction price. Change orders are evaluated on a contract-by-contract basis to determine if they should be accounted for as a new contract or as part of the existing contract. Generally, services from change orders are not distinct from the original performance obligation. As a result, the effect that the contract modification has on the contract revenue, and measure of progress, is recognized as an adjustment to revenue when they occur. Costs of Revenue Costs of revenue include (i) compensation and benefits for billable employees and personnel involved in production, data management and delivery, and the costs of acquiring and processing data for the Company’s information offerings; (ii) costs of staff directly involved with delivering technology-related services offerings and engagements, and the costs of data purchased specifically for technology services engagements; (iii) reimbursed expenses that are comprised principally of payments to investigators who oversee clinical trials and travel expenses for the Company’s clinical monitors and sales representatives; and (iv) other expenses directly related to service contracts such as courier fees, laboratory supplies, professional services and travel expenses. Trade Receivables, Unbilled Services and Unearned Income In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company’s services under the contract. In general, the Company’s intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise from long-term contracts when a cost-based or hours-based input method of revenue recognition is utilized and revenue recognized exceeds the amount billed to the customer. Unearned income consists of advance payments and billings in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue is recognized, the unearned income balance is reduced by the amount of the revenue recognized during the period. Unearned income is classified as a current liability on the condensed consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year. Recently Issued Accounting Standards Accounting pronouncements adopted In March 2017, the FASB issued new accounting guidance that requires the service cost component of net periodic benefit cost be presented in the same income statement line item as other employee compensation costs, and requires that the other components of net periodic benefit expense be recognized in the non-operating section of the income statement. In addition, only the service cost component of net periodic benefit expense is eligible for capitalization when applicable. The Company adopted this new accounting guidance on January 1, 2018. In January 2017, the FASB issued new accounting guidance that changes the definition of a business to clarify when a set of assets does not constitute a business. Under the new definition, when substantially all of the fair value of gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set of assets is generally not a business. The Company adopted this new accounting guidance on January 1, 2018. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In January 2016, the FASB issued new accounting guidance that modifies how entities measure equity investments and present changes in the fair value of financial liabilities (“ASU 2016-01”). The Company adopted this new accounting guidance on January 1, 2018. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements “Financial Instruments – Overall (Topic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.” In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers (“ASU 2014-09”). The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted ASU 2014-09 on January 1, 2018 using the full retrospective method. See “Revenue Recognition” and “Adjustments to Previously Reported Financial Statements from the Adoption of Accounting Pronouncements” included elsewhere in Note 1 for further discussion regarding the effects of the adoption of ASU 2014-09. Adjustments to Previously Reported Financial Statements from the Adoption of Accounting Pronouncements The following table presents the effect of the adoption of ASU 2014-09 on the Company’s condensed consolidated balance sheet as of December 31, 2017 (in millions): December 31, 2017 As Previously Reported As Recast Trade accounts receivable and unbilled services, net $ 1,993 $ 2,097 Total current assets 3,450 3,554 Deferred income taxes 98 109 Total assets 22,742 22,857 Unearned income 733 985 Total current liabilities 2,904 3,156 Deferred income taxes 918 895 Total liabilities 14,384 14,613 Retained earnings 655 538 Accumulated other comprehensive income 46 49 Equity attributable to IQVIA Holdings Inc.’s stockholders 8,109 7,995 Total stockholders’ equity 8,358 8,244 Total liabilities and stockholders’ equity 22,742 22,857 The following table presents the effect of the adoption of ASU 2014-09 and ASU 2017-07 on the Company’s condensed consolidated statement of income for the three months ended March 31, 2017 (in millions, except per share amounts): Three Months Ended March 31, 2017 As Previously Reported As Recast Total revenues $ 2,322 $ 2,360 Cost of revenues, exclusive of depreciation and amortization 1,523 1,526 Selling, general and administrative expenses 380 381 Income from operations 168 202 Other expense (income), net 3 (1 ) Income before income taxes and equity in earnings of unconsolidated affiliates 89 127 Income tax expense 12 24 Income before equity in earnings of unconsolidated affiliates 77 103 Net income 76 102 Net income attributable to IQVIA Holdings Inc. 74 100 Earnings per share attributable to common stockholders: Basic $ 0.32 $ 0.43 Diluted $ 0.31 $ 0.43 Adoption of the above standards had no impact to cash from or used in operating, financing, or investing activities on the Company’s condensed consolidated statement of cash flow for the three months ended March 31, 2017. Accounting pronouncements being evaluated In February 2018, the FASB issued new accounting guidance that will allow a reclassification from accumulated other comprehensive income to retained earnings for “stranded tax effects” resulting from the Tax Act. Because the income statement impact related to the reduction of the historical corporate income tax rate under the Tax Act is required to be included in income tax expense, the guidance acknowledges that the tax effects of items within accumulated other comprehensive income (“stranded tax effects”) do not reflect the appropriate tax rate. The new accounting guidance will be effective for the Company on January 1, 2019. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In August 2017, the FASB issued new accounting guidance that will allow more financial and nonfinancial hedging strategies to be eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess hedge effectiveness. It is intended to more closely align hedge accounting with risk management strategies, simplify the application of hedge accounting, and increase transparency as to the scope and results of hedging programs. The new accounting guidance will be effective for the Company on January 1, 2019. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In February 2016, the FASB issued new accounting guidance that requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. The income statement will reflect lease expense for operating leases, and amortization and interest expense for financing leases. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements.

Revenues by Geography, Concentr

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations	3 Months Ended
	Mar. 31, 2018
Revenue From Contract With Customer [Abstract]
Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations	2. Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations The following tables represent revenues by geographic region and reportable segment for the three months ended March 31, 2018 and 2017: Three Months Ended March 31, 2018 (in millions) Commercial Solutions Research & Development Solutions Integrated Engagement Services Total Revenues: Americas $ 471 $ 608 $ 93 $ 1,172 Europe and Africa 378 447 65 890 Asia-Pacific 136 310 55 501 Total revenues $ 985 $ 1,365 $ 213 $ 2,563 Three Months Ended March 31, 2017 (in millions) Commercial Solutions Research & Development Solutions Integrated Engagement Services Total Revenues: Americas $ 412 $ 603 $ 113 $ 1,128 Europe and Africa 323 410 62 795 Asia-Pacific 128 250 59 437 Total revenues $ 863 $ 1,263 $ 234 $ 2,360 No customer accounted for 10% or more of consolidated revenues for the three months ended March 31, 2018 or 2017. Transaction Price Allocated to the Remaining Performance Obligations As of March 31, 2018, approximately $17.6 billion of revenue is expected to be recognized in the future from remaining performance obligations. The Company expects to recognize revenue on approximately 40% of these wholly unperformed contracts where the customer has a unilateral right to cancel the arrangement. The Company applied the practical expedient that permits the omission of prior period information about its remaining performance obligations. No other practical expedients were applied.

Trade Accounts Receivable, Unbi

Trade Accounts Receivable, Unbilled Services and Unearned Income	3 Months Ended
	Mar. 31, 2018
Receivables [Abstract]
Trade Accounts Receivable, Unbilled Services and Unearned Income	3. Trade Accounts Receivable, Unbilled Services and Unearned Income Trade accounts receivables and unbilled services consist of the following: (in millions) March 31, 2018 December 31, 2017 Trade accounts receivable: Billed $ 1,235 $ 1,229 Unbilled services 1,032 883 Trade accounts receivable and unbilled services 2,267 2,112 Allowance for doubtful accounts (17 ) (15 ) Trade accounts receivable and unbilled services, net $ 2,250 $ 2,097 Unbilled services and unearned income was as follows: (in millions, except percentages) March 31, 2018 December 31, 2017 $ Change % Change Unbilled services $ 1,032 $ 883 $ 149 16.9 % Unearned income (934 ) (985 ) 51 (5.2 ) Net balance $ 98 $ (102 ) $ 200 (196.1 )% Unbilled services, which is comprised of approximately equal parts of unbilled receivables and contract assets as of March 31, 2018, increased by $149 million as compared to December 31, 2017. Contract assets are unbilled services for which invoicing is based on the timing of certain milestones related to service contracts for clinical research whereas unbilled receivables are billable upon the passage of time. Unearned income also decreased by $51 million over the same period resulting in an increase of $200 million in the net balance of unbilled services and unearned income between December 31, 2017 and March 31, 2018. These fluctuations are primarily due to timing of payments and invoicing related to the Company’s Research and Development Solutions contracts. Bad debt expense recognized on the Company’s receivables and unbilled services was de minimis for the three months ended March 31, 2018 and 2017.

Investments-Debt, Equity and Ot

Investments-Debt, Equity and Other Securities	3 Months Ended
	Mar. 31, 2018
Investments Debt And Equity Securities [Abstract]
Investments-Debt, Equity and Other Securities	4. Investments – Debt, Equity and Other Securities Current The Company’s short-term investments in debt, equity and other securities consist primarily of trading investments in mutual funds and are measured at fair value with realized and unrealized gains and losses recorded in other expense (income), net on the accompanying condensed consolidated statements of income. Long-term ASU 2016-01 became effective on January 1, 2018. ASU 2016-01 requires entities to measure equity investments (except those accounted for under the equity method, those that result in consolidation of the investee and certain other investments) at fair value and recognize any changes in fair value in net income at the end of each reporting period. Entities can no longer classify equity investments as trading or available for sale, and can no longer recognize unrealized holding gains and losses on equity securities classified previously as available for sale in other comprehensive income (loss) For equity investments that do not have readily determinable fair values and do not qualify for the existing practical expedient in Accounting Standards Codification (“ASC”) 820 “Fair Value Measurement” (“ASC 820”) to estimate fair value using the net asset value per share of the investment, the guidance provides a new measurement alternative. Entities may choose to measure those investments at cost, less any impairment, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer at each reporting period. The Company adopted ASU 2016-01 on January 1, 2018, however its long-term investments in debt, equity and other securities were only $8 million as of December 31, 2017. As a result, the adoption of the new guidance did not have a material impact as it relates to the Company’s previously reported investments. In February 2018, the Company invested $20 million in COTA, Inc. (“COTA”) for a minority ownership interest. The Company’s investment in COTA does not meet the criteria to be accounted for under the equity method or to be consolidated and as a result is subject to ASU 2016-01 noted above. The Company’s investment in COTA does not have a readily determinable fair value and does not qualify for the existing practical expedient in ASC 820. The Company has elected to utilize the new measurement alternative provided for in ASC 321 “Investments – Equity Securities.”

Variable Interest Entities

Variable Interest Entities	3 Months Ended
	Mar. 31, 2018
Variable Interest Entity Not Primary Beneficiary Disclosures [Abstract]
Variable Interest Entities	5. Variable Interest Entities As of March 31, 2018, the Company’s investments in unconsolidated variable interest entities (“VIEs”) and its estimated maximum exposure to loss were as follows: (in millions) Investments in Unconsolidated VIEs Maximum Exposure to Loss NovaQuest Pharma Opportunities Fund III, L.P. (“NovaQuest Fund III”) $ 34 $ 41 NovaQuest Pharma Opportunities Fund IV, L.P. (“NovaQuest Fund IV”) 8 16 Pappas Life Science Ventures V, L.P. (“Pappas Fund V”) 1 5 $ 43 $ 62 The Company investments in and advances to unconsolidated affiliates

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill	6. Goodwill The following is a summary of goodwill by reportable segment for the three months ended March 31, 2018: Research & Integrated Commercial Development Engagement (in millions) Solutions Solutions Services Consolidated Balance as of December 31, 2017 $ 10,348 $ 1,385 $ 117 $ 11,850 Business combinations 7 — — 7 Impact of foreign currency fluctuations and other 177 5 2 184 Balance as of March 31, 2018 $ 10,532 $ 1,390 $ 119 $ 12,041

Derivatives

Derivatives	3 Months Ended
	Mar. 31, 2018
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivatives	7. Derivatives Foreign Exchange Risk Management As of March 31, 2018, the Company held foreign currency forward contracts to (i) hedge certain forecasted foreign exchange cash flows arising from service contracts (“Service Contract Hedging”) and (ii) hedge non-United States dollar anticipated intercompany royalties (“Royalty Hedging”). It is the Company’s policy to enter into foreign currency transactions only to the extent necessary to reduce earnings and cash flow volatility associated with foreign exchange rate movements. The Company does not enter into foreign currency transactions for investment or speculative purposes. As of March 31, 2018, the Company had open Service Contract Hedging and Royalty Hedging contracts to hedge certain forecasted foreign currency cash flow transactions occurring in 2018 with notional amounts totaling $279 million. For accounting purposes these hedges are considered highly effective. As of March 31, 2018 and December 31, 2017, the Company had recorded gross unrealized gains (losses) of $5 million and ($6) million and $5 million and ($4) million, respectively, related to these contracts. Upon expiration of the hedge instruments during 2018, the Company will reclassify the unrealized holding gains and losses on the derivative instruments included in accumulated other comprehensive income (loss) (“AOCI”) into earnings. The unrealized gains (losses) are included in other current assets and liabilities on the accompanying condensed consolidated balance sheets as of March 31, 2018 and December 31, 2017. Interest Rate Risk Management The Company purchases interest rate caps and has entered into interest rate swap agreements for purposes of managing its exposure to interest rate fluctuations. In April 2014, IMS Health Holdings, Inc. (“IMS Health”), one of the predecessors to the Company prior to the merger of Quintiles Transnational Holdings Inc. (“Quintiles”) and IMS Health, purchased three United States dollar denominated interest rate caps (“2014 Caps”) with a total notional value of $1 billion at strike prices between 2% and 3%. These caps were effective at various times between April 2014 and April 2016 and expire in April 2019. The 2014 Caps are accounted for as cash flow hedges. As of March 31, 2018, only two of the 2014 Caps remain unexpired, with a notional value of $700 million. IMS Health also entered into three United States dollar and Euro denominated interest rate swap agreements in April 2014 (“2014 Swaps”) to hedge interest rate exposure on notional amounts of approximately $600 million of its borrowings. The 2014 Swaps were effective between April and June 2014, and expire at various times through March 2021. As of March 31, 2018, only two of the 2014 Swaps remain unexpired, with a notional value of $457 million. On these agreements, the Company pays a fixed rate ranging from 1.6% to 2.1% and receives a variable rate of interest equal to the greater of three-month United States dollar London Interbank Offered Rate (“LIBOR”) or three-month Euro Interbank Offered Rate (“EURIBOR”), and 1%. During 2017, the 2014 Swaps ceased to be considered highly effective for accounting purposes and as such, the Company discontinued hedge accounting and prospective changes in the fair value of the Swaps are recognized in earnings. On June 3, 2015, the Company entered into seven forward starting interest rate swaps (“2015 Swaps”) in an effort to limit its exposure to changes in the variable interest rate on its senior secured credit facilities. Interest on the swaps began accruing on June 30, 2016, and the interest rate swaps expire at various times through March 2020. As of March 31, 2018, only four of the 2015 Swaps were still outstanding. The Company pays a fixed rate ranging from 1.9% to 2.1% and receives a variable rate of interest equal to the three-month LIBOR on the outstanding agreements. The critical terms of the 2015 Swaps are substantially the same as the underlying borrowings. These interest rate swaps are being accounted for as cash flow hedges as these transactions were executed to hedge the Company’s interest payments and for accounting purposes are considered highly effective. As such, the effective portion of the hedges is recorded as unrealized gains (losses) on derivatives included in AOCI and the ineffective portion of the hedges is recognized in earnings. The fair value of these interest rate swaps represents the present value of the anticipated net payments the Company will make to the counterparty, which, when they occur, are reflected as interest expense on the consolidated statements of income. These interest rate swaps will result in a total debt mix of approximately 55% fixed rate debt and 45% variable rate debt, before the additional protection arising from the interest rate caps. Net Investment Risk Management The Company designates its foreign currency denominated debt as a hedge of its net investment in certain foreign subsidiaries to reduce the volatility in stockholders’ equity caused by changes in the Euro exchange rate with respect to the United States dollar. As of March 31, 2018, these borrowings (net of original issue discount) were €4,028 million ($4,965 million). The effective portion of foreign exchange gains or losses on the remeasurement of the debt is recognized in the cumulative translation adjustment component of AOCI with the related offset in long-term debt. Those amounts will be reclassified from AOCI to earnings upon the sale or substantial liquidation of these net investments. The amount of foreign exchange losses related to the net investment hedge included in the cumulative translation adjustment component of AOCI for the three months ended March 31, 2018 was $140 million. The fair values of the Company’s derivative instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table: March 31, 2018 December 31, 2017 (in millions) Balance Sheet Classification Assets Liabilities Notional Assets Liabilities Notional Derivatives designated as hedging instruments: Foreign exchange forward contracts Other current assets and liabilities $ 5 $ 6 $ 279 $ 5 $ 4 $ 282 Interest rate swaps Other assets and liabilities 3 — 390 — 1 405 Interest rate caps Deposits and other assets 2 — 700 1 — 700 Derivatives not designated as hedging instruments: Interest rate swaps Other liabilities — 7 457 — 8 447 Total derivatives $ 10 $ 13 $ 6 $ 13 The effect of the Company’s cash flow hedging instruments on other comprehensive (loss) income is summarized in the following table: Three Months Ended March 31, (in millions) 2018 2017 Foreign exchange forward contracts $ (2 ) $ (1 ) Interest rate swaps 5 3 Total $ 3 $ 2

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	8. Fair Value Measurements The Company records certain assets and liabilities at fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A three-level fair value hierarchy that prioritizes the inputs used to measure fair value is described below. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: • Level 1 — Quoted prices in active markets for identical assets or liabilities. • Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data. • Level 3 — Unobservable inputs that are supported by little or no market activity. This includes certain pricing models, discounted cash flow methodologies and similar techniques that use significant unobservable inputs. The carrying values of cash, cash equivalents, accounts receivable and accounts payable approximated their fair values at March 31, 2018 and December 31, 2017 due to their short-term nature. At March 31, 2018 and December 31, 2017, the fair value of total debt approximated $10,523 million and $10,432 million, respectively, as determined under Level 2 measurements based on quoted prices for these financial instruments. Recurring Fair Value Measurements The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured and reported at fair value on a recurring basis as of March 31, 2018: (in millions) Level 1 Level 2 Level 3 Total Assets: Trading securities $ 47 $ — $ — $ 47 Derivatives — 10 — 10 Total $ 47 $ 10 $ — $ 57 Liabilities: Derivatives $ — $ 13 $ — $ 13 Contingent consideration — — 60 60 Total $ — $ 13 $ 60 $ 73 Below is a summary of the valuation techniques used in determining fair value: Trading securities — The Company values trading securities using the quoted market value of the securities held. Derivatives — Derivatives consist of foreign exchange contracts and interest rate caps and swaps. The fair value of foreign exchange contracts is based on observable market inputs of spot and forward rates or using other observable inputs. The fair value of the interest rate caps and swaps is the estimated amount that the Company would receive or pay to terminate such agreements, taking into account market interest rates and the remaining time to maturities or using market inputs with mid-market pricing as a practical expedient for bid-ask spread. Contingent consideration — The Company values contingent consideration related to business combinations using a weighted probability calculation of potential payment scenarios discounted at rates reflective of the risks associated with the expected future cash flows. Key assumptions used to estimate the fair value of contingent consideration include various financial metrics (revenue performance targets and operating forecasts) and the probability of achieving the specific targets. The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the three months ended March 31: Contingent Consideration – Accounts Payable and Accrued Expenses (in millions) 2018 2017 Balance as of January 1 $ 69 $ 18 Business combinations 7 — Contingent consideration paid (14 ) — Revaluations included in earnings and foreign currency translation adjustments (2 ) — Balance as of March 31 $ 60 $ 18 Revaluations of the contingent consideration are recognized in other expense (income), net on the accompanying condensed consolidated statements of income.

Credit Arrangements

Credit Arrangements	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Credit Arrangements	9. Credit Arrangements The following is a summary of the Company’s revolving credit facilities at March 31, 2018: Facility Interest Rates $1,000 million (revolving credit facility) LIBOR in the relevant currency borrowed plus a margin of 2.00% at March 31, 2018 $25 million (receivables financing facility) LIBOR Market Index Rate (1.88% at March 31, 2018) plus 0.90% £10 million (approximately $14 million) general banking facility with a European headquartered bank Bank’s base rate of 0.50% at March 31, 2018 plus 1% The following table summarizes the Company’s debt at the dates indicated: (in millions) March 31, 2018 December 31, 2017 Senior Secured Credit Facilities: Term A Loan due 2021—U.S. Dollar LIBOR at average floating rates of 4.30% $ 833 $ 844 Term A Loan due 2021—Euro LIBOR at average floating rates of 2.00% 460 453 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 4.30% 746 748 Term B Loan due 2024—U.S. Dollar LIBOR at average floating rates of 4.30% 1,185 1,188 Term B Loan due 2024—Euro LIBOR at average floating rates of 2.75% 1,461 1,423 Revolving Credit Facility due 2021: U.S. Dollar denominated borrowings — floating rates of 3.75% 634 529 5.0% Senior Notes due 2026 — 1,050 1,050 2.875% Senior Notes due 2025—Euro denominated 518 503 3.25% Senior Notes due 2025 — 1,756 1,707 3.5% Senior Notes due 2024 — 770 749 4.875% Senior Notes due 2023—U.S. Dollar denominated 800 800 Receivables financing facility due 2020—U.S. Dollar LIBOR at average floating rate of 2.78% 275 275 Principal amount of debt 10,488 10,269 Less: unamortized discount and debt issuance costs (42 ) (44 ) Less: current portion (104 ) (103 ) Long-term debt $ 10,342 $ 10,122 Contractual maturities of long-term debt are as follows at March 31, 2018: (in millions) Remainder of 2018 $ 78 2019 104 2020 379 2021 1,769 2022 34 Thereafter 8,124 $ 10,488 At March 31, 2018, there were bank guarantees totaling approximately £3 million (approximately $4 million) issued against the availability of the general banking facility. During the first three months of 2018, the Company borrowed and repaid $405 million and $300 million, respectively, under its revolving credit facilities. Senior Secured Facilities At March 31, 2018, the Company’s senior credit facility provided financing of up to approximately $5,685 million, which consisted of $5,319 million principal amount of debt outstanding (as detailed in the table above) and $366 million of available borrowing capacity on the $1,000 million revolving credit facility that expires in 2021. On April 6, 2018, the Company entered into Amendment No. 3 to its Fourth Amended and Restated Credit Agreement that increased the amount of commitments available to the Company and certain of its subsidiaries to $1,500 million under the revolving credit facility. No other terms of the credit agreement were amended. Restrictive Covenants The Company’s debt agreements provide for certain covenants and events of default customary for similar instruments, including a covenant not to exceed a specified ratio of consolidated senior secured net indebtedness to consolidated EBITDA, as defined in the senior credit facility agreement and a covenant to maintain a specified minimum interest coverage ratio. If an event of default occurs under any of the Company’s or the Company’s subsidiaries’ financing arrangements, the creditors under such financing arrangements will be entitled to take various actions, including the acceleration of amounts due under such arrangements, and in the case of the lenders under the revolving credit facility and term loans, other actions permitted to be taken by a secured creditor. The Company’s long-term debt arrangements contain other usual and customary restrictive covenants that, among other things, place limitations on the Company’s ability to declare dividends. At March 31, 2018, the Company was in compliance with the financial covenants under its debt agreements in all material respects.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Stockholders' Equity	10. Stockholders’ Equity Preferred Stock The Company is authorized to issue 1.0 million shares of preferred stock, $0.01 per share par value. No shares of preferred stock were issued or outstanding as of March 31, 2018 or December 31, 2017. Equity Repurchase Program On February 14, 2018, the Board increased the stock repurchase authorization under a previously approved equity repurchase program (the “Repurchase Program”) by $1.5 billion, which increased the total amount that has been authorized under the Repurchase Program to $5.725 billion since the plan’s inception in October 2013. The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock, and it may be modified, extended, suspended or discontinued at any time. During the first quarter of 2018, the Company repurchased 874,627 shares of its common stock for approximately $86 million. As of March 31, 2018, the Company has remaining authorization to repurchase up to $1.6 billion of its common stock under the Repurchase Program. In addition, from time to time, the Company has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program. Non-controlling Interests In July 2015, the Company contributed businesses to a joint venture with Quest Diagnostics Incorporated (“Quest”) that was recorded at book value (carryover basis) because the Company owns 60% of the joint venture and maintains control of these businesses. Quest’s 40% non-controlling interest in the joint venture, referred to as Q 2 2018 2017 Balance as of January 1 $ 249 $ 227 Comprehensive income: Net income 4 2 Foreign currency adjustments, net of income tax 4 — Balance as of March 31 $ 257 $ 229

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2018
Business Combinations [Abstract]
Business Combinations	11. Business Combinations The Company completed several immaterial acquisitions during the three months ended March 31, 2018. The Company’s assessment of fair value and the purchase price allocation related to these acquisitions is preliminary and subject to change upon completion. Further adjustments may be necessary as additional information related to the fair values of assets acquired and liabilities assumed is assessed during the measurement period (up to one year from the acquisition date). The condensed consolidated financial statements include the results of the acquisitions subsequent to their respective closing dates. Pro forma information is not presented for these acquisitions as the aggregate operations of the acquired businesses were not significant to the overall operations of the Company. The following table provides certain financial information for these acquisitions, including the preliminary allocation of the purchase price to certain tangible and intangible assets acquired and goodwill: Amortization (in millions) Period 2018 Total cost of acquisitions, net of cash acquired (1) $ 31 Amounts recorded in the Condensed Consolidated Balance Sheets: Goodwill 7 Portion of goodwill deductible for income tax purposes — Intangible assets: Customer relationships 8-10 years 20 Non-compete agreements 5 years 1 Software 2-5 years 4 Total intangible assets $ 25 (1) Total cost of acquisitions, net of cash acquired, includes contingent consideration and deferred purchase payments of $11 million.

Restructuring

Restructuring	3 Months Ended
	Mar. 31, 2018
Restructuring And Related Activities [Abstract]
Restructuring	12. Restructuring The Company has taken restructuring actions in 2018, 2017 and 2016 to align its resources and reduce overcapacity to adapt to changing market conditions and integrate acquisitions. These actions include closing facilities, consolidating functional activities, eliminating redundant positions, and aligning resources with customer requirements. Restructuring expense in the first three months of 2018 consisted of severance and related costs of $25 million and facility exit costs of $1 million. These restructuring actions are expected to continue into 2019. The following amounts were recorded for the restructuring plans: (in millions) Severance and Related Costs Exit Costs Total Balance at December 31, 2017 $ 80 $ 4 $ 84 Expense, net of reversals 25 1 26 Payments (23 ) (1 ) (24 ) Foreign currency translation and other 2 — 2 Balance at March 31, 2018 $ 84 $ 4 $ 88 Restructuring costs are not allocated to the Company’s reportable segments as they are not part of the segment performance measures regularly reviewed by management. The Company expects that the majority of the restructuring accruals at March 31, 2018 will be paid in 2018 and 2019.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes On December 22, 2017, the U.S. government enacted the Tax Act. The Tax Act is comprehensive legislation that includes provisions that lower the federal corporate income tax rate from 35% to 21% beginning in 2018 and impose a one-time transition tax on undistributed foreign earnings. ASC 740 “Income Taxes” generally requires the effects of the tax law change to be recorded in the period of enactment. However, the SEC staff issued Staff Accounting Bulletin No. 118 to address situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. The Company has recognized the tax impacts related to the transition tax on undistributed foreign earnings and the impact to deferred tax assets and liabilities and included these amounts in its consolidated financial statements for the year ended December 31, 2017, on a provisional basis. The ultimate impact may differ from these provisional amounts, possibly materially, due to among other things, additional analysis, changes in interpretations and assumptions the Company has made, and additional interpretive regulatory guidance that may be issued. The accounting is expected to be complete when the 2017 U.S. corporate income tax return is filed in 2018. The effective income tax rate was 22.4% and 18.9% in the first quarter of 2018 and 2017, respectively. In the first quarter of 2018, the effective income tax rate was favorably impacted by the reduction in the U.S. statutory tax rate to 21% as a result of the Tax Act. This favorability was partially offset by an increased U.S. tax base as a result of the Tax Act. For the three months ended March 31, 2018 and 2017, the effective income tax rate was also favorably impacted by a tax benefit of $47 million and $64 million, respectively, related to purchase accounting amortization of approximately $207 million and $182 million, respectively, as a result of the merger between Quintiles and IMS Health. The favorable impact related to purchase accounting in 2018 was substantially less than in 2017 due to the reduction in the U.S. statutory tax rate to 21% in 2018.

Employee Benefit Plans

Employee Benefit Plans	3 Months Ended
	Mar. 31, 2018
Postemployment Benefits [Abstract]
Employee Benefit Plans	14. Employee Benefit Plans The following table summarizes the components of net periodic benefit cost for the Company’s pension benefits: Three Months Ended March 31, (in millions) 2018 2017 Service cost $ 10 $ 9 Interest cost 5 5 Expected return on plan assets (11 ) (9 ) $ 4 $ 5 Interest cost and expected return on plan assets are recorded in other expense (income), net on the accompanying condensed consolidated statements of income. The above tables do not include the Company’s expense associated with providing certain executives with supplemental pension benefits as well as postretirement medical, dental and life insurance benefits in accordance with their individual employment arrangements. The Company’s net periodic expense related to these benefits for the three months ended March 31, 2018 was de minimis.

Comprehensive Income

Comprehensive Income	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Comprehensive Income	15. Comprehensive Income Below is a summary of the components of AOCI: (in millions) Foreign Currency Translation Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2017 $ (214 ) $ 14 $ 30 $ 219 $ 49 Other comprehensive income before reclassifications 163 1 — 40 204 Reclassification adjustments — 2 — (1 ) 1 Balance at March 31, 2018 $ (51 ) $ 17 $ 30 $ 258 $ 254 Below is a summary of the adjustments for (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item: Affected Financial Statement Three Months Ended March 31, (in millions) Line Item 2018 2017 Derivative instruments: Foreign exchange forward contracts Revenues $ (2 ) $ 5 Foreign exchange forward contracts Other expense (income), net 4 (3 ) Total before income taxes 2 2 Income tax benefit 1 — Total net of income taxes $ 1 $ 2

Segments

Segments	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Segments	16. Segments The following table presents the Company’s operations by reportable segment. The Company is managed through three reportable segments, Commercial Solutions, Research & Development Solutions and Integrated Engagement Services. Commercial Solutions provides mission critical information, technology solutions and real-world insights and services to the Company’s life science customers. Research & Development Solutions, which primarily serves biopharmaceutical customers, provides outsourced clinical research and clinical trial related services. Integrated Engagement Services provides health care provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. Certain costs are not allocated to the Company’s segments and are reported as general corporate and unallocated expenses. These costs primarily consist of stock-based compensation and expenses for corporate overhead functions such as senior leadership, finance, human resources, information technology, facilities and legal. The Company does not allocate depreciation and amortization or restructuring costs to its segments. Asset information by segment is not presented, as this measure is not used by the chief operating decision maker to assess the Company’s performance. The Company’s reportable segment information is presented below: Three Months Ended March 31, (in millions) 2018 2017 Revenues Commercial Solutions $ 985 $ 863 Research & Development Solutions 1,365 1,263 Integrated Engagement Services 213 234 Total revenues 2,563 2,360 Costs of revenue, exclusive of depreciation and amortization Commercial Solutions 547 467 Research & Development Solutions 923 863 Integrated Engagement Services 182 196 Total costs of revenue 1,652 1,526 Selling, general and administrative expenses Commercial Solutions 185 164 Research & Development Solutions 156 136 Integrated Engagement Services 18 19 General corporate and unallocated 61 62 Total selling, general and administrative expenses 420 381 Segment profit Commercial Solutions 253 232 Research & Development Solutions 286 264 Integrated Engagement Services 13 19 Total segment profit 552 515 General corporate and unallocated (61 ) (62 ) Depreciation and amortization (282 ) (232 ) Restructuring costs (26 ) (19 ) Total income from operations $ 183 $ 202

Earnings Per Share

Earnings Per Share	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Earnings Per Share	17. Earnings Per Share The following table presents the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share because they are subject to performance conditions or the effect of including such stock-based awards in the computation would be anti-dilutive: Three Months Ended March 31, (in millions) 2018 2017 Shares subject to performance conditions 0.7 0.3 Shares subject to anti-dilutive stock-based awards 1.1 1.3 Total shares excluded from diluted earnings per share 1.8 1.6 The vesting of performance awards is contingent upon the achievement of certain performance targets. The performance awards are not included in diluted earnings per share until the performance targets have been met. Stock-based awards will have a dilutive effect under the treasury method when the respective period’s average market value of the Company’s common stock exceeds the exercise proceeds.

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Unaudited Interim Financial Information	Unaudited Interim Financial Information The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair statement of the Company’s financial condition and results of operations have been included. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the Company’s audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017.
Income Taxes	Income Taxes Income tax expense includes United States (“U.S”) federal, state and international income taxes. Certain items of income and expense are not reported in income tax returns and financial statements in the same year. The income tax effects of these differences are reported as deferred income taxes. Valuation allowances are provided to reduce the related deferred income tax assets to an amount which will, more likely than not, be realized. As a result of the Tax Cuts and Jobs Act (the “Tax Act”) enacted on December 22, 2017, the Company no longer considers the undistributed earnings of its foreign subsidiaries to be indefinitely reinvested and will record deferred income taxes on these earnings, as applicable. The Company has provisionally recorded their U.S. deferred taxes based on the Federal corporate income tax rate of 21%. The Company is continuing to analyze aspects of the Tax Act and, therefore, has not finalized its accounting policy with respect to whether to (1) recognize deferred taxes for basis differences expected to reverse as Global Low Taxed Intangible Income (“GILTI”) or (2) account for GILTI as period costs if and when incurred. The Company has not recognized any deferred tax impacts related to GILTI or the Base Erosion Anti Abuse Tax (“BEAT”) on a provisional basis. Interest and penalties related to unrecognized income tax benefits are recognized as a component of income tax expense.
Revenue Recognition	Revenue Recognition The Company’s arrangements are primarily service contracts that range in duration from a few months to several years. The Company recognizes revenue when control of these services is transferred to the customer in an amount, referred to as the transaction price, that reflects the consideration to which the Company is expected to be entitled in exchange for those goods or services. The Company determines revenue recognition utilizing the following five steps: (1) identification of the contract with a customer, (2) identification of the performance obligations in the contract (promised goods or services that are distinct), (3) determination of the transaction price, (4) allocation of the transaction price to the performance obligations, and (5) recognition of revenue when, or as, the Company transfers control of the product or service for each performance obligation. Cash payments made to customers as incentives to induce the customers to enter into service agreements with the Company are amortized as a reduction of revenue over the period the services are performed. The Company records revenues net of any tax assessments by governmental authorities, such as value added taxes, that are imposed on and concurrent with specific revenue generating transactions. The Company derives the majority of its revenues in the Commercial Solutions segment from various information and technology service offerings. Information offerings (primarily under fixed-price contracts) typically include multiple performance obligations including an ongoing subscription-based deliverable for which revenue is recognized ratably as earned over the contract period, and/or a one-time deliverable of data offerings for which revenue is recognized upon delivery. The customer is able to benefit from the provision of data as it is received. The Company’s subscription arrangements typically have terms ranging from one to three years and are generally non-cancelable and do not contain refund-type provisions. Technology services offerings may contain multiple performance obligations consisting of a mix of small and large-scale services and consulting projects, multi-year outsourcing contracts and Software-as-a-Service (“SaaS”) arrangements. These arrangements typically have terms ranging from several weeks to three years, with a majority having terms of one year or less. For arrangements that include multiple performance obligations, the transaction price is allocated to the identified performance obligations based on their relative standalone selling prices. For these contracts, the standalone selling prices are based on the Company’s normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics and geographic location. Revenues for services engagements where the transfer of control occurs ratably over time are recognized on a straight-line basis over the term of the arrangement. Revenues from time and material contracts are recognized based on hours as the services are provided. Revenues from fixed price ad hoc services and consulting contracts are recognized over the contract term based on the ratio of the number of hours incurred for services provided during the period compared to the total estimated hours to be incurred over the entire arrangement (hours-based). Technology services offerings meet the over time criterion, as another party would not need to substantially re-perform the work already completed to satisfy the remaining obligations if the services were migrated to another party. The majority of the Company’s contracts within the Research & Development Solutions segment are service contracts for clinical research that represent a single performance obligation. The Company provides a significant integration service resulting in a combined output, which is clinical trial data that meets the relevant regulatory standards and can be used by the customer to progress to the next phase of a clinical trial or solicit approval of a treatment by the applicable regulatory body. The performance obligation is satisfied over time as the output is captured in data and documentation that is available for the customer to consume over the course of the arrangement and furthers progress of the clinical trial. The Company recognizes revenue over time using a cost-based based input method since there is no single output measure that would fairly depict the transfer of control over the life of the performance obligation. Progress on the performance obligation is measured by the proportion of actual costs incurred to the total costs expected to complete the contract. Costs included in the measure of progress include direct labor and third-party costs (such as payments to investigators and travel expenses for the Company’s clinical monitors). This cost-based method of revenue recognition requires the Company to make estimates of costs to complete its projects on an ongoing basis. Significant judgment is required to evaluate assumptions related to these estimates. The effect of revisions to estimates related to the transaction price or costs to complete a project are recorded in the period in which the estimate is revised. Most contracts may be terminated upon 30 to 90 days notice by the customer; however, in the event of termination, a substantive termination penalty requires payment for services rendered through the date of termination, as well as for subsequent services rendered to close out the contract. The Company derives the majority of its revenues in its Integrated Engagement Services segment by providing contract sales and market access professionals to customers within the biopharmaceutical industry on a fee-for-service basis. Some of the Company’s Integrated Engagement Services contracts contain multiple performance obligations with distinct promises including recruiting, sales force automation and deployment of sales representatives. The nature of the terms of these performance obligations will vary based on the customized needs of the customer. For contracts that have multiple performance obligations, the standalone selling prices of the Company’s performance obligations are not directly observable since they are rarely sold standalone. Therefore, the Company estimates the standalone selling prices using an expected cost plus a margin approach under which expected costs of satisfying a performance obligation are forecasted and added to an appropriate margin for that distinct good or service. The Company utilizes a single measure of progress for each performance obligation to recognize revenue, which includes deployment of sales representatives based on employee days worked; recruiting based on candidates recruited; sales force automation set-up based on hours worked; and sales force automation hosting and maintenance based on usage. These services meet the over time criterion as the customer consumes the benefit as activities are performed and another party would not need to substantially re-perform the work already completed to satisfy the remaining obligations if the services were migrated to another party. Variable Consideration In some cases, contracts provide for variable consideration that is contingent upon the occurrence of uncertain future events, such as performance incentives (including royalty payments or penalty clauses that can either increase or decrease the transaction price). Variable consideration is estimated at the expected value or at the most likely amount depending on the type of consideration. Estimated amounts are included in the transaction price to the extent it is probable that a significant reversal of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is resolved. The estimate of variable consideration and determination of whether to include estimated amounts in the transaction price are based largely on an assessment of its anticipated performance and all information (historical, current and forecasted) that is reasonably available to the Company. Reimbursed Expenses The Company includes reimbursed expenses in revenues and costs of revenue as the Company is primarily responsible for fulfilling the promise to provide the specified service, including the integration of the related services into a combined output to the customer, which are inseparable from the integrated service. These costs include such items as payments to investigators and travel expenses for the Company’s clinical monitors and sales representatives, over which the Company has discretion in establishing prices. The Company controls the good or service and has inventory risk on contractually reimbursable expenses, as sometimes the Company is unable to obtain reimbursement from the customer for costs incurred. Change Orders Changes in the scope of work are common, especially under long-term contracts, and generally result in a change in transaction price. Change orders are evaluated on a contract-by-contract basis to determine if they should be accounted for as a new contract or as part of the existing contract. Generally, services from change orders are not distinct from the original performance obligation. As a result, the effect that the contract modification has on the contract revenue, and measure of progress, is recognized as an adjustment to revenue when they occur. Costs of Revenue Costs of revenue include (i) compensation and benefits for billable employees and personnel involved in production, data management and delivery, and the costs of acquiring and processing data for the Company’s information offerings; (ii) costs of staff directly involved with delivering technology-related services offerings and engagements, and the costs of data purchased specifically for technology services engagements; (iii) reimbursed expenses that are comprised principally of payments to investigators who oversee clinical trials and travel expenses for the Company’s clinical monitors and sales representatives; and (iv) other expenses directly related to service contracts such as courier fees, laboratory supplies, professional services and travel expenses. Trade Receivables, Unbilled Services and Unearned Income In general, billings and payments are established by contractual provisions including predetermined payment schedules, which may or may not correspond to the timing of the transfer of control of the Company’s services under the contract. In general, the Company’s intention in its invoicing (payment terms) is to maintain cash neutrality over the life of the contract. Upfront payments, when they occur, are intended to cover certain expenses the Company incurs at the beginning of the contract. Neither the Company nor its customers view such upfront payments and contracted payment schedules as a means of financing. Unbilled services primarily arise from long-term contracts when a cost-based or hours-based input method of revenue recognition is utilized and revenue recognized exceeds the amount billed to the customer. Unearned income consists of advance payments and billings in excess of revenue recognized. As the contracted services are subsequently performed and the associated revenue is recognized, the unearned income balance is reduced by the amount of the revenue recognized during the period. Unearned income is classified as a current liability on the condensed consolidated balance sheet as the Company expects to recognize the associated revenue in less than one year.
Recently Issued Accounting Standards	Recently Issued Accounting Standards Accounting pronouncements adopted In March 2017, the FASB issued new accounting guidance that requires the service cost component of net periodic benefit cost be presented in the same income statement line item as other employee compensation costs, and requires that the other components of net periodic benefit expense be recognized in the non-operating section of the income statement. In addition, only the service cost component of net periodic benefit expense is eligible for capitalization when applicable. The Company adopted this new accounting guidance on January 1, 2018. In January 2017, the FASB issued new accounting guidance that changes the definition of a business to clarify when a set of assets does not constitute a business. Under the new definition, when substantially all of the fair value of gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set of assets is generally not a business. The Company adopted this new accounting guidance on January 1, 2018. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements. In January 2016, the FASB issued new accounting guidance that modifies how entities measure equity investments and present changes in the fair value of financial liabilities (“ASU 2016-01”). The Company adopted this new accounting guidance on January 1, 2018. The adoption of this new accounting guidance did not have a material effect on the Company’s consolidated financial statements “Financial Instruments – Overall (Topic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.” In May 2014, the FASB and the International Accounting Standards Board issued a converged standard on the recognition of revenue from contracts with customers (“ASU 2014-09”). The objective of the new standard is to establish a single comprehensive revenue recognition model that is designed to create greater comparability of financial statements across industries and jurisdictions. Under the new standard, companies will recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration to which the company expects to be entitled in exchange for those goods or services. The Company adopted ASU 2014-09 on January 1, 2018 using the full retrospective method. See “Revenue Recognition” and “Adjustments to Previously Reported Financial Statements from the Adoption of Accounting Pronouncements” included elsewhere in Note 1 for further discussion regarding the effects of the adoption of ASU 2014-09. Adjustments to Previously Reported Financial Statements from the Adoption of Accounting Pronouncements The following table presents the effect of the adoption of ASU 2014-09 on the Company’s condensed consolidated balance sheet as of December 31, 2017 (in millions): December 31, 2017 As Previously Reported As Recast Trade accounts receivable and unbilled services, net $ 1,993 $ 2,097 Total current assets 3,450 3,554 Deferred income taxes 98 109 Total assets 22,742 22,857 Unearned income 733 985 Total current liabilities 2,904 3,156 Deferred income taxes 918 895 Total liabilities 14,384 14,613 Retained earnings 655 538 Accumulated other comprehensive income 46 49 Equity attributable to IQVIA Holdings Inc.’s stockholders 8,109 7,995 Total stockholders’ equity 8,358 8,244 Total liabilities and stockholders’ equity 22,742 22,857 The following table presents the effect of the adoption of ASU 2014-09 and ASU 2017-07 on the Company’s condensed consolidated statement of income for the three months ended March 31, 2017 (in millions, except per share amounts): Three Months Ended March 31, 2017 As Previously Reported As Recast Total revenues $ 2,322 $ 2,360 Cost of revenues, exclusive of depreciation and amortization 1,523 1,526 Selling, general and administrative expenses 380 381 Income from operations 168 202 Other expense (income), net 3 (1 ) Income before income taxes and equity in earnings of unconsolidated affiliates 89 127 Income tax expense 12 24 Income before equity in earnings of unconsolidated affiliates 77 103 Net income 76 102 Net income attributable to IQVIA Holdings Inc. 74 100 Earnings per share attributable to common stockholders: Basic $ 0.32 $ 0.43 Diluted $ 0.31 $ 0.43 Adoption of the above standards had no impact to cash from or used in operating, financing, or investing activities on the Company’s condensed consolidated statement of cash flow for the three months ended March 31, 2017. Accounting pronouncements being evaluated In February 2018, the FASB issued new accounting guidance that will allow a reclassification from accumulated other comprehensive income to retained earnings for “stranded tax effects” resulting from the Tax Act. Because the income statement impact related to the reduction of the historical corporate income tax rate under the Tax Act is required to be included in income tax expense, the guidance acknowledges that the tax effects of items within accumulated other comprehensive income (“stranded tax effects”) do not reflect the appropriate tax rate. The new accounting guidance will be effective for the Company on January 1, 2019. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In August 2017, the FASB issued new accounting guidance that will allow more financial and nonfinancial hedging strategies to be eligible for hedge accounting. It also amends the presentation and disclosure requirements and changes how companies assess hedge effectiveness. It is intended to more closely align hedge accounting with risk management strategies, simplify the application of hedge accounting, and increase transparency as to the scope and results of hedging programs. The new accounting guidance will be effective for the Company on January 1, 2019. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements. In February 2016, the FASB issued new accounting guidance that requires lessees to recognize almost all leases on their balance sheet as a right-of-use asset and a lease liability. The income statement will reflect lease expense for operating leases, and amortization and interest expense for financing leases. The new accounting guidance will be effective for annual reporting periods beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this new accounting guidance on its consolidated financial statements.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Schedule of Adjustments to Previously Reported Financial Statements from the Adoption of Accounting Pronouncements	The following table presents the effect of the adoption of ASU 2014-09 on the Company’s condensed consolidated balance sheet as of December 31, 2017 (in millions): December 31, 2017 As Previously Reported As Recast Trade accounts receivable and unbilled services, net $ 1,993 $ 2,097 Total current assets 3,450 3,554 Deferred income taxes 98 109 Total assets 22,742 22,857 Unearned income 733 985 Total current liabilities 2,904 3,156 Deferred income taxes 918 895 Total liabilities 14,384 14,613 Retained earnings 655 538 Accumulated other comprehensive income 46 49 Equity attributable to IQVIA Holdings Inc.’s stockholders 8,109 7,995 Total stockholders’ equity 8,358 8,244 Total liabilities and stockholders’ equity 22,742 22,857 The following table presents the effect of the adoption of ASU 2014-09 and ASU 2017-07 on the Company’s condensed consolidated statement of income for the three months ended March 31, 2017 (in millions, except per share amounts): Three Months Ended March 31, 2017 As Previously Reported As Recast Total revenues $ 2,322 $ 2,360 Cost of revenues, exclusive of depreciation and amortization 1,523 1,526 Selling, general and administrative expenses 380 381 Income from operations 168 202 Other expense (income), net 3 (1 ) Income before income taxes and equity in earnings of unconsolidated affiliates 89 127 Income tax expense 12 24 Income before equity in earnings of unconsolidated affiliates 77 103 Net income 76 102 Net income attributable to IQVIA Holdings Inc. 74 100 Earnings per share attributable to common stockholders: Basic $ 0.32 $ 0.43 Diluted $ 0.31 $ 0.43

Revenues by Geography, Concen27

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations (Tables)	3 Months Ended
	Mar. 31, 2018
Revenue From Contract With Customer [Abstract]
Summary of Revenues by Geographic Region and Reportable Segment	The following tables represent revenues by geographic region and reportable segment for the three months ended March 31, 2018 and 2017: Three Months Ended March 31, 2018 (in millions) Commercial Solutions Research & Development Solutions Integrated Engagement Services Total Revenues: Americas $ 471 $ 608 $ 93 $ 1,172 Europe and Africa 378 447 65 890 Asia-Pacific 136 310 55 501 Total revenues $ 985 $ 1,365 $ 213 $ 2,563 Three Months Ended March 31, 2017 (in millions) Commercial Solutions Research & Development Solutions Integrated Engagement Services Total Revenues: Americas $ 412 $ 603 $ 113 $ 1,128 Europe and Africa 323 410 62 795 Asia-Pacific 128 250 59 437 Total revenues $ 863 $ 1,263 $ 234 $ 2,360

Trade Accounts Receivable, Un28

Trade Accounts Receivable, Unbilled Services and Unearned Income (Tables)	3 Months Ended
	Mar. 31, 2018
Receivables [Abstract]
Trade Accounts Receivable and Unbilled Services	Trade accounts receivables and unbilled services consist of the following: (in millions) March 31, 2018 December 31, 2017 Trade accounts receivable: Billed $ 1,235 $ 1,229 Unbilled services 1,032 883 Trade accounts receivable and unbilled services 2,267 2,112 Allowance for doubtful accounts (17 ) (15 ) Trade accounts receivable and unbilled services, net $ 2,250 $ 2,097
Schedule of Net Contract Assets (Liabilities)	Unbilled services and unearned income was as follows: (in millions, except percentages) March 31, 2018 December 31, 2017 $ Change % Change Unbilled services $ 1,032 $ 883 $ 149 16.9 % Unearned income (934 ) (985 ) 51 (5.2 ) Net balance $ 98 $ (102 ) $ 200 (196.1 )%

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	3 Months Ended
	Mar. 31, 2018
Variable Interest Entity Not Primary Beneficiary Disclosures [Abstract]
Summary of Investments in Unconsolidated Variable Interest Entities and Estimated Maximum Exposure to Loss	As of March 31, 2018, the Company’s investments in unconsolidated variable interest entities (“VIEs”) and its estimated maximum exposure to loss were as follows: (in millions) Investments in Unconsolidated VIEs Maximum Exposure to Loss NovaQuest Pharma Opportunities Fund III, L.P. (“NovaQuest Fund III”) $ 34 $ 41 NovaQuest Pharma Opportunities Fund IV, L.P. (“NovaQuest Fund IV”) 8 16 Pappas Life Science Ventures V, L.P. (“Pappas Fund V”) 1 5 $ 43 $ 62

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Summary of Goodwill by Reportable Segment	The following is a summary of goodwill by reportable segment for the three months ended March 31, 2018: Research & Integrated Commercial Development Engagement (in millions) Solutions Solutions Services Consolidated Balance as of December 31, 2017 $ 10,348 $ 1,385 $ 117 $ 11,850 Business combinations 7 — — 7 Impact of foreign currency fluctuations and other 177 5 2 184 Balance as of March 31, 2018 $ 10,532 $ 1,390 $ 119 $ 12,041

Derivatives (Tables)

Derivatives (Tables)	3 Months Ended
	Mar. 31, 2018
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Summary of Fair Values of Derivative Instruments Designated as Hedges	The fair values of the Company’s derivative instruments and the line items on the accompanying condensed consolidated balance sheets to which they were recorded are summarized in the following table: March 31, 2018 December 31, 2017 (in millions) Balance Sheet Classification Assets Liabilities Notional Assets Liabilities Notional Derivatives designated as hedging instruments: Foreign exchange forward contracts Other current assets and liabilities $ 5 $ 6 $ 279 $ 5 $ 4 $ 282 Interest rate swaps Other assets and liabilities 3 — 390 — 1 405 Interest rate caps Deposits and other assets 2 — 700 1 — 700 Derivatives not designated as hedging instruments: Interest rate swaps Other liabilities — 7 457 — 8 447 Total derivatives $ 10 $ 13 $ 6 $ 13
Effect of Cash Flow Hedging Instruments on Other Comprehensive (Loss) Income	The effect of the Company’s cash flow hedging instruments on other comprehensive (loss) income is summarized in the following table: Three Months Ended March 31, (in millions) 2018 2017 Foreign exchange forward contracts $ (2 ) $ (1 ) Interest rate swaps 5 3 Total $ 3 $ 2

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value of Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the fair value of the Company’s financial assets and liabilities that are measured and reported at fair value on a recurring basis as of March 31, 2018: (in millions) Level 1 Level 2 Level 3 Total Assets: Trading securities $ 47 $ — $ — $ 47 Derivatives — 10 — 10 Total $ 47 $ 10 $ — $ 57 Liabilities: Derivatives $ — $ 13 $ — $ 13 Contingent consideration — — 60 60 Total $ — $ 13 $ 60 $ 73
Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis	The following table summarizes the changes in Level 3 financial assets and liabilities measured on a recurring basis for the three months ended March 31: Contingent Consideration – Accounts Payable and Accrued Expenses (in millions) 2018 2017 Balance as of January 1 $ 69 $ 18 Business combinations 7 — Contingent consideration paid (14 ) — Revaluations included in earnings and foreign currency translation adjustments (2 ) — Balance as of March 31 $ 60 $ 18

Credit Arrangements (Tables)

Credit Arrangements (Tables)	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Summary of Credit Facilities	The following is a summary of the Company’s revolving credit facilities at March 31, 2018: Facility Interest Rates $1,000 million (revolving credit facility) LIBOR in the relevant currency borrowed plus a margin of 2.00% at March 31, 2018 $25 million (receivables financing facility) LIBOR Market Index Rate (1.88% at March 31, 2018) plus 0.90% £10 million (approximately $14 million) general banking facility with a European headquartered bank Bank’s base rate of 0.50% at March 31, 2018 plus 1%
Summary of Debt	The following table summarizes the Company’s debt at the dates indicated: (in millions) March 31, 2018 December 31, 2017 Senior Secured Credit Facilities: Term A Loan due 2021—U.S. Dollar LIBOR at average floating rates of 4.30% $ 833 $ 844 Term A Loan due 2021—Euro LIBOR at average floating rates of 2.00% 460 453 Term B Loan due 2025—U.S. Dollar LIBOR at average floating rates of 4.30% 746 748 Term B Loan due 2024—U.S. Dollar LIBOR at average floating rates of 4.30% 1,185 1,188 Term B Loan due 2024—Euro LIBOR at average floating rates of 2.75% 1,461 1,423 Revolving Credit Facility due 2021: U.S. Dollar denominated borrowings — floating rates of 3.75% 634 529 5.0% Senior Notes due 2026 — 1,050 1,050 2.875% Senior Notes due 2025—Euro denominated 518 503 3.25% Senior Notes due 2025 — 1,756 1,707 3.5% Senior Notes due 2024 — 770 749 4.875% Senior Notes due 2023—U.S. Dollar denominated 800 800 Receivables financing facility due 2020—U.S. Dollar LIBOR at average floating rate of 2.78% 275 275 Principal amount of debt 10,488 10,269 Less: unamortized discount and debt issuance costs (42 ) (44 ) Less: current portion (104 ) (103 ) Long-term debt $ 10,342 $ 10,122
Contractual Maturities of Long-term Debt	Contractual maturities of long-term debt are as follows at March 31, 2018: (in millions) Remainder of 2018 $ 78 2019 104 2020 379 2021 1,769 2022 34 Thereafter 8,124 $ 10,488

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Summary of Non-controlling Interests	2018 2017 Balance as of January 1 $ 249 $ 227 Comprehensive income: Net income 4 2 Foreign currency adjustments, net of income tax 4 — Balance as of March 31 $ 257 $ 229

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2018
Business Combinations [Abstract]
Schedule of Preliminary Allocation of Purchase to Certain Tangible and Intangible Assets Acquired and Goodwill	The following table provides certain financial information for these acquisitions, including the preliminary allocation of the purchase price to certain tangible and intangible assets acquired and goodwill: Amortization (in millions) Period 2018 Total cost of acquisitions, net of cash acquired (1) $ 31 Amounts recorded in the Condensed Consolidated Balance Sheets: Goodwill 7 Portion of goodwill deductible for income tax purposes — Intangible assets: Customer relationships 8-10 years 20 Non-compete agreements 5 years 1 Software 2-5 years 4 Total intangible assets $ 25

Restructuring (Tables)

Restructuring (Tables)	3 Months Ended
	Mar. 31, 2018
Restructuring And Related Activities [Abstract]
Summary of Amounts Recorded for Restructuring Plans	The following amounts were recorded for the restructuring plans: (in millions) Severance and Related Costs Exit Costs Total Balance at December 31, 2017 $ 80 $ 4 $ 84 Expense, net of reversals 25 1 26 Payments (23 ) (1 ) (24 ) Foreign currency translation and other 2 — 2 Balance at March 31, 2018 $ 84 $ 4 $ 88

Employee Benefit Plans (Tables)

Employee Benefit Plans (Tables)	3 Months Ended
	Mar. 31, 2018
Compensation And Retirement Disclosure [Abstract]
Summary of Components of Net Periodic Benefit Cost for Pension Benefits	The following table summarizes the components of net periodic benefit cost for the Company’s pension benefits: Three Months Ended March 31, (in millions) 2018 2017 Service cost $ 10 $ 9 Interest cost 5 5 Expected return on plan assets (11 ) (9 ) $ 4 $ 5

Comprehensive Income (Tables)

Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Summary of Components of AOCI	Below is a summary of the components of AOCI: (in millions) Foreign Currency Translation Derivative Instruments Defined Benefit Plans Income Taxes Total Balance at December 31, 2017 $ (214 ) $ 14 $ 30 $ 219 $ 49 Other comprehensive income before reclassifications 163 1 — 40 204 Reclassification adjustments — 2 — (1 ) 1 Balance at March 31, 2018 $ (51 ) $ 17 $ 30 $ 258 $ 254
Summary of Adjustments for (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item	Below is a summary of the adjustments for (gains) losses reclassified from AOCI into the condensed consolidated statements of income and the affected financial statement line item: Affected Financial Statement Three Months Ended March 31, (in millions) Line Item 2018 2017 Derivative instruments: Foreign exchange forward contracts Revenues $ (2 ) $ 5 Foreign exchange forward contracts Other expense (income), net 4 (3 ) Total before income taxes 2 2 Income tax benefit 1 — Total net of income taxes $ 1 $ 2

Segments (Tables)

Segments (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Reconciliation of Revenues and Income from Segments to Consolidated	Asset information by segment is not presented, as this measure is not used by the chief operating decision maker to assess the Company’s performance. The Company’s reportable segment information is presented below: Three Months Ended March 31, (in millions) 2018 2017 Revenues Commercial Solutions $ 985 $ 863 Research & Development Solutions 1,365 1,263 Integrated Engagement Services 213 234 Total revenues 2,563 2,360 Costs of revenue, exclusive of depreciation and amortization Commercial Solutions 547 467 Research & Development Solutions 923 863 Integrated Engagement Services 182 196 Total costs of revenue 1,652 1,526 Selling, general and administrative expenses Commercial Solutions 185 164 Research & Development Solutions 156 136 Integrated Engagement Services 18 19 General corporate and unallocated 61 62 Total selling, general and administrative expenses 420 381 Segment profit Commercial Solutions 253 232 Research & Development Solutions 286 264 Integrated Engagement Services 13 19 Total segment profit 552 515 General corporate and unallocated (61 ) (62 ) Depreciation and amortization (282 ) (232 ) Restructuring costs (26 ) (19 ) Total income from operations $ 183 $ 202

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Summary of Weighted-Average Outstanding Stock Based Awards Excluded from Computation of Diluted Earnings Per Share	The following table presents the weighted average number of outstanding stock-based awards not included in the computation of diluted earnings per share because they are subject to performance conditions or the effect of including such stock-based awards in the computation would be anti-dilutive: Three Months Ended March 31, (in millions) 2018 2017 Shares subject to performance conditions 0.7 0.3 Shares subject to anti-dilutive stock-based awards 1.1 1.3 Total shares excluded from diluted earnings per share 1.8 1.6

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2018EmployeeCountry	Dec. 31, 2017
Summary Of Significant Accounting Policies [Line Items]
Number of employees | Employee	55,000
Federal corporate income tax rate	21.00%	35.00%
Revenue, contract termination description	Most contracts may be terminated upon 30 to 90 days notice by the customer; however, in the event of termination, a substantive termination penalty requires payment for services rendered through the date of termination, as well as for subsequent services rendered to close out the contract.
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Number of countries | Country	100
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Unearned income recognition period	1 year

Summary of Significant Accoun42

Summary of Significant Accounting Policies - Effect of Adoption of ASU 2014-09 on Condensed Consolidated Balance Sheet (Detail) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Trade accounts receivable and unbilled services, net	$ 2,250	$ 2,097
Total current assets	3,724	3,554
Deferred income taxes	113	109
Total assets	23,235	22,857
Unearned income	934	985
Total current liabilities	3,199	3,156
Deferred income taxes	828	895
Total liabilities	14,782	14,613
Retained earnings	605	538
Accumulated other comprehensive income	254	49
Equity attributable to IQVIA Holdings Inc.’s stockholders	8,196	7,995
Total stockholders’ equity	8,453	8,244
Total liabilities and stockholders’ equity	$ 23,235	22,857
As Previously Reported [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Trade accounts receivable and unbilled services, net		1,993
Total current assets		3,450
Deferred income taxes		98
Total assets		22,742
Unearned income		733
Total current liabilities		2,904
Deferred income taxes		918
Total liabilities		14,384
Retained earnings		655
Accumulated other comprehensive income		46
Equity attributable to IQVIA Holdings Inc.’s stockholders		8,109
Total stockholders’ equity		8,358
Total liabilities and stockholders’ equity		22,742
Accounting Standards Update 2014-09 [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Trade accounts receivable and unbilled services, net		2,097
Total current assets		3,554
Deferred income taxes		109
Total assets		22,857
Unearned income		985
Total current liabilities		3,156
Deferred income taxes		895
Total liabilities		14,613
Retained earnings		538
Accumulated other comprehensive income		49
Equity attributable to IQVIA Holdings Inc.’s stockholders		7,995
Total stockholders’ equity		8,244
Total liabilities and stockholders’ equity		$ 22,857

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Effect of Adoption of ASU 2017-07 and ASU 2014-09 on Condensed Consolidated Statement of Income (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Revenues	$ 2,563	$ 2,360
Costs of revenue, exclusive of depreciation and amortization	1,652	1,526
Selling, general and administrative expenses	420	381
Income from operations	183	202
Other expense (income), net	(4)	1
Income before income taxes and equity in earnings of unconsolidated affiliates	85	127
Income tax expense	19	24
Income before equity in earnings of unconsolidated affiliates	66	103
Net income	73	102
Net income attributable to IQVIA Holdings Inc.	$ 69	$ 100
Earnings per share attributable to common stockholders:
Basic	$ 0.33	$ 0.43
Diluted	$ 0.32	$ 0.43
As Previously Reported [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Revenues		$ 2,322
Costs of revenue, exclusive of depreciation and amortization		1,523
Selling, general and administrative expenses		380
Income from operations		168
Other expense (income), net		3
Income before income taxes and equity in earnings of unconsolidated affiliates		89
Income tax expense		12
Income before equity in earnings of unconsolidated affiliates		77
Net income		76
Net income attributable to IQVIA Holdings Inc.		$ 74
Earnings per share attributable to common stockholders:
Basic		$ 0.32
Diluted		$ 0.31
Accounting Standards Update 2017-07 and 2014-09 [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Revenues		$ 2,360
Costs of revenue, exclusive of depreciation and amortization		1,526
Selling, general and administrative expenses		381
Income from operations		202
Other expense (income), net		(1)
Income before income taxes and equity in earnings of unconsolidated affiliates		127
Income tax expense		24
Income before equity in earnings of unconsolidated affiliates		103
Net income		102
Net income attributable to IQVIA Holdings Inc.		$ 100
Earnings per share attributable to common stockholders:
Basic		$ 0.43
Diluted		$ 0.43

Revenues by Geography, Concen44

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Summary of Revenues by Geographic Region and Reportable Segment (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Disaggregation Of Revenue [Line Items]
Total revenues	$ 2,563	$ 2,360
Americas [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	1,172	1,128
Europe and Africa [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	890	795
Asia-Pacific [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	501	437
Commercial Solutions [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	985	863
Commercial Solutions [Member] | Americas [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	471	412
Commercial Solutions [Member] | Europe and Africa [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	378	323
Commercial Solutions [Member] | Asia-Pacific [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	136	128
Research & Development Solutions [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	1,365	1,263
Research & Development Solutions [Member] | Americas [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	608	603
Research & Development Solutions [Member] | Europe and Africa [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	447	410
Research & Development Solutions [Member] | Asia-Pacific [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	310	250
Integrated Engagement Services [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	213	234
Integrated Engagement Services [Member] | Americas [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	93	113
Integrated Engagement Services [Member] | Europe and Africa [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	65	62
Integrated Engagement Services [Member] | Asia-Pacific [Member]
Disaggregation Of Revenue [Line Items]
Total revenues	$ 55	$ 59

Revenues by Geography, Concen45

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Additional Information 1 (Detail) $ in Billions	3 Months Ended
	Mar. 31, 2018USD ($)Customer	Mar. 31, 2017Customer
Revenue From Contract With Customer [Abstract]
Number of clients served | Customer	0	0
Revenue expected to be recognized in future from remaining performance obligations | $	$ 17.6

Revenues by Geography, Concen46

Revenues by Geography, Concentration of Credit Risk and Remaining Performance Obligations - Additional Information 2 (Detail) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2018-04-01	3 Months Ended
	Mar. 31, 2018
Disaggregation Of Revenue [Line Items]
Percentage of remaining performance obligations on which revenue is expected to be recognized	40.00%
Unearned income recognition period	1 year

Trade Accounts Receivable, Un47

Trade Accounts Receivable, Unbilled Services and Unearned Income - Trade Accounts Receivable and Unbilled Services (Detail) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Trade accounts receivable:
Billed	$ 1,235	$ 1,229
Unbilled services	1,032	883
Trade accounts receivable and unbilled services	2,267	2,112
Allowance for doubtful accounts	(17)	(15)
Trade accounts receivable and unbilled services, net	$ 2,250	$ 2,097

Trade Accounts Receivable, Un48

Trade Accounts Receivable, Unbilled Services and Unearned Income - Schedule of Net Contract Assets (Liabilities) (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Contract With Customer Asset And Liability [Abstract]
Unbilled services	$ 1,032	$ 883
Unearned income	(934)	(985)
Net balance	98	$ (102)
Unbilled Services, Change	149
Unearned Income, Change	51
Net balance, Change	$ 200
Unbilled Services, Percentage	16.90%
Unearned Income, Percentage	(5.20%)
Net balance, Percentage	(196.10%)

Trade Accounts Receivable, Un49

Trade Accounts Receivable, Unbilled Services and Unearned Income - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Receivables [Abstract]
Increase in unbilled services	$ 149
Decrease in unearned income	51
Increase of net balance of unbilled services and unearned income	$ 200

Investments - Debt, Equity and

Investments - Debt, Equity and Other Securities - Additional Information (Detail) - USD ($) $ in Millions	Mar. 31, 2018	Feb. 28, 2018	Dec. 31, 2017
Investments Debt And Equity Securities [Line Items]
Long-term investments in debt, equity and other securities	$ 28		$ 8
COTA Inc [Member] | Minority Ownership Interest [Member]
Investments Debt And Equity Securities [Line Items]
Investments for minority ownership interest		$ 20

Variable Interest Entities - Su

Variable Interest Entities - Summary of Investments in Unconsolidated Variable Interest Entities and Estimated Maximum Exposure to Loss (Detail)	Mar. 31, 2018USD ($)
Variable Interest Entity [Line Items]
Maximum Exposure to Loss	$ 62,000,000
NovaQuest Pharma Opportunities Fund lll, L.P ("NovaQuest Fund lll") [Member]
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	34,000,000
Maximum Exposure to Loss	41,000,000
NovaQuest Pharma Opportunities Fund lV, L.P ("NovaQuest Fund lV") [Member]
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	8,000,000
Maximum Exposure to Loss	16,000,000
Pappas Life Science Ventures V, LP ("Pappas Fund V") [Member]
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	1,000,000
Maximum Exposure to Loss	5,000,000
Variable Interest Entity Primary Beneficiary [Member]
Variable Interest Entity [Line Items]
Investments in Unconsolidated VIEs	$ 43,000,000

Goodwill - Summary of Goodwill

Goodwill - Summary of Goodwill by Reportable Segment (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Goodwill [Line Items]
Beginning Balance	$ 11,850
Business combinations	7
Impact of foreign currency fluctuations and other	184
Ending Balance	12,041
Commercial Solutions [Member]
Goodwill [Line Items]
Beginning Balance	10,348
Business combinations	7
Impact of foreign currency fluctuations and other	177
Ending Balance	10,532
Research & Development Solutions [Member]
Goodwill [Line Items]
Beginning Balance	1,385
Impact of foreign currency fluctuations and other	5
Ending Balance	1,390
Integrated Engagement Services [Member]
Goodwill [Line Items]
Beginning Balance	117
Impact of foreign currency fluctuations and other	2
Ending Balance	$ 119

Derivatives - Additional Inform

Derivatives - Additional Information (Detail) € in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2018USD ($)Agreement	Dec. 31, 2017USD ($)	Mar. 31, 2018EUR (€)Agreement	Jun. 03, 2015Agreement	Apr. 30, 2014USD ($)Agreement
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Interest swaps accrual beginning date	Jun. 30, 2016
Borrowings, net of original issue discount	$ 10,488,000,000
Foreign exchange losses related to net investment hedge	140,000,000
Foreign Currency Denominated Debt [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Borrowings, net of original issue discount	$ 4,965,000,000		€ 4,028
IMS Health Holdings, Inc. [Member] | Derivatives Designated As Cash Flow Hedges [Member] | LIBOR [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative variable interest rates					1.00%
IMS Health Holdings, Inc. [Member] | Derivatives Designated As Cash Flow Hedges [Member] | EURIBOR [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative variable interest rates					1.00%
Maximum [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Interest rate swaps expiry date	Mar. 31, 2020
Service Contract Hedging and Royalty Hedging Contracts [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Notional amount	$ 279,000,000
Gains related to contracts	5,000,000	$ 5,000,000
Losses related to contracts	$ (6,000,000)	$ (4,000,000)
Expiration year of hedge instruments	2,018
Interest Rate Cap [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Notional amount	$ 700,000,000
Interest Rate Cap [Member] | IMS Health Holdings, Inc. [Member] | Derivatives Designated As Cash Flow Hedges [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Notional amount					$ 1,000,000,000
Number of interest rate contracts | Agreement	2		2		3
Effective description of interest rate swaps	Effective at various times between April 2014 and April 2016
Expiration description of interest rate swaps	Expire in April 2019
Interest Rate Cap [Member] | Minimum [Member] | IMS Health Holdings, Inc. [Member] | Derivatives Designated As Cash Flow Hedges [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Interest rate caps range of strike rates					2.00%
Interest Rate Cap [Member] | Maximum [Member] | IMS Health Holdings, Inc. [Member] | Derivatives Designated As Cash Flow Hedges [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Interest rate caps range of strike rates					3.00%
2014 Swaps [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Notional amount	$ 457,000,000
2014 Swaps [Member] | IMS Health Holdings, Inc. [Member] | Derivatives Designated As Cash Flow Hedges [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Notional amount					$ 600,000,000
Number of interest rate contracts | Agreement	2		2		3
Effective description of interest rate swaps	Effective between April and June 2014
Expiration description of interest rate swaps	Expire at various times through March 2021
2014 Swaps [Member] | Minimum [Member] | IMS Health Holdings, Inc. [Member] | Derivatives Designated As Cash Flow Hedges [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative swap interest rate					1.60%
2014 Swaps [Member] | Maximum [Member] | IMS Health Holdings, Inc. [Member] | Derivatives Designated As Cash Flow Hedges [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative swap interest rate					2.10%
2015 Swaps [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Number of interest rate contracts | Agreement	4		4	7
2015 Swaps [Member] | Minimum [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative fixed interest rate	1.90%		1.90%
2015 Swaps [Member] | Maximum [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Derivative fixed interest rate	2.10%		2.10%
Swaps [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Interest rate swaps, Fixed rate debt percent	55.00%		55.00%
Interest rate swaps, Variable rate debt percent	45.00%		45.00%

Derivatives - Summary of Fair V

Derivatives - Summary of Fair Values of Derivative Instruments Designated as Hedges (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Derivatives Fair Value [Line Items]
Derivative asset fair value	$ 10,000,000	$ 6,000,000
Derivative liability fair value	13,000,000	13,000,000
2014 Swaps [Member]
Derivatives Fair Value [Line Items]
Derivative notional amount	457,000,000
Interest Rate Cap [Member]
Derivatives Fair Value [Line Items]
Derivative notional amount	700,000,000
Designated as Hedging Instrument [Member] | Other Current Assets and Liabilities [Member] | Foreign Exchange Forward Contracts [Member]
Derivatives Fair Value [Line Items]
Derivative asset fair value	5,000,000	5,000,000
Derivative liability fair value	6,000,000	4,000,000
Derivative notional amount	279,000,000	282,000,000
Designated as Hedging Instrument [Member] | Other Assets and Liabilities [Member] | 2014 Swaps [Member]
Derivatives Fair Value [Line Items]
Derivative asset fair value	3,000,000
Derivative liability fair value		1,000,000
Derivative notional amount	390,000,000	405,000,000
Designated as Hedging Instrument [Member] | Deposits and Other Assets [Member] | Interest Rate Cap [Member]
Derivatives Fair Value [Line Items]
Derivative asset fair value	2,000,000	1,000,000
Derivative notional amount	700,000,000	700,000,000
Not Designated as Hedging Instrument [Member] | Other Liabilities [Member] | 2014 Swaps [Member]
Derivatives Fair Value [Line Items]
Derivative liability fair value	7,000,000	8,000,000
Derivative notional amount	$ 457,000,000	$ 447,000,000

Derivatives - Effect of Cash Fl

Derivatives - Effect of Cash Flow Hedging Instruments on Other Comprehensive (Loss) Income (Detail) - Derivatives Designated As Cash Flow Hedges [Member] - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ 3	$ 2
Foreign Exchange Forward Contracts [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	(2)	(1)
Swaps [Member]
Derivative Instruments And Hedging Activities Disclosures [Line Items]
Effect of cash flow hedging instruments on other comprehensive income (loss)	$ 5	$ 3

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of total debt	$ 10,523	$ 10,432

Fair Value Measurements - Fair

Fair Value Measurements - Fair Value of Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Recurring Fair Value Measurements [Member] $ in Millions	Mar. 31, 2018USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 57
Fair value of liabilities	73
Derivatives [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	10
Fair value of liabilities	13
Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	60
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	47
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	10
Fair value of liabilities	13
Level 2 [Member] | Derivatives [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	10
Fair value of liabilities	13
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	60
Level 3 [Member] | Contingent Consideration [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of liabilities	60
Trading Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	47
Trading Securities [Member] | Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of assets	$ 47

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Liabilities Measured on Recurring Basis (Detail) - Accounts Payable And Accrued Expenses - Contingent Consideration [Member] - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance, Contingent Consideration	$ 69	$ 18
Business combinations	7	0
Contingent consideration paid	(14)	0
Revaluations included in earnings and foreign currency translation adjustments	(2)	0
Ending Balance, Contingent Consideration	$ 60	$ 18

Credit Arrangements - Summary o

Credit Arrangements - Summary of Credit Facilities (Detail)	3 Months Ended
	Mar. 31, 2018USD ($)	Mar. 31, 2018GBP (£)
Revolving credit facility [Member]
Line Of Credit Facility [Line Items]
Facility	$ 1,000,000,000
Interest Rate Description	LIBOR in the relevant currency borrowed plus a margin of 2.00% at March 31, 2018
Revolving credit facility [Member] | LIBOR [Member]
Line Of Credit Facility [Line Items]
Rate	2.00%	2.00%
Receivables Financing Facility [Member]
Line Of Credit Facility [Line Items]
Facility	$ 25,000,000
Interest Rate Description	LIBOR Market Index Rate (1.88% at March 31, 2018) plus 0.90%
Receivables Financing Facility [Member] | LIBOR [Member]
Line Of Credit Facility [Line Items]
Rate	1.88%	1.88%
Interest Rate spread on base rate	0.90%
General Banking Facility [Member]
Line Of Credit Facility [Line Items]
Facility	$ 14,000,000	£ 10,000,000
Interest Rate Description	Bank’s base rate of 0.50% at March 31, 2018 plus 1%
General Banking Facility [Member] | Base Rate [Member]
Line Of Credit Facility [Line Items]
Rate	0.50%	0.50%
Interest Rate spread on base rate	1.00%

Credit Arrangements - Summary60

Credit Arrangements - Summary of Debt (Detail) - USD ($) $ in Millions	Mar. 31, 2018	Dec. 31, 2017
Senior Secured Credit Facilities:
Principal amount of debt	$ 10,488	$ 10,269
Less: unamortized discount and debt issuance costs	(42)	(44)
Less: current portion	(104)	(103)
Long-term debt	10,342	10,122
U.S Dollars [Member] | Due in 2021 [Member] | Revolving credit facility [Member] | LIBOR [Member]
Senior Secured Credit Facilities:
Principal amount of debt	634	529
U.S Dollars [Member] | Due in 2021 [Member] | Senior Secured Term A Loan [Member] | LIBOR [Member]
Senior Secured Credit Facilities:
Principal amount of debt	833	844
U.S Dollars [Member] | Due in 2025 [Member] | Senior Secured Term B Loan [Member] | LIBOR [Member]
Senior Secured Credit Facilities:
Principal amount of debt	746	748
U.S Dollars [Member] | Due in 2024 [Member] | Senior Secured Term B Loan [Member] | LIBOR [Member]
Senior Secured Credit Facilities:
Principal amount of debt	1,185	1,188
U.S Dollars [Member] | Due in 2026 [Member] | 5.0% Senior Notes [Member]
Senior Secured Credit Facilities:
Principal amount of debt	1,050	1,050
U.S Dollars [Member] | Due in 2023 [Member] | 4.875% Senior Notes [Member]
Senior Secured Credit Facilities:
Principal amount of debt	800	800
U.S Dollars [Member] | Due in 2020 [Member] | Receivables Financing Facility [Member] | LIBOR [Member]
Senior Secured Credit Facilities:
Principal amount of debt	275	275
EUR Dollars [Member] | Due in 2021 [Member] | Senior Secured Term A Loan [Member] | LIBOR [Member]
Senior Secured Credit Facilities:
Principal amount of debt	460	453
EUR Dollars [Member] | Due in 2025 [Member] | 2.875% Senior Notes [Member]
Senior Secured Credit Facilities:
Principal amount of debt	518	503
EUR Dollars [Member] | Due in 2025 [Member] | 3.25% Senior Notes [Member]
Senior Secured Credit Facilities:
Principal amount of debt	1,756	1,707
EUR Dollars [Member] | Due in 2024 [Member] | Senior Secured Term B Loan [Member] | LIBOR [Member]
Senior Secured Credit Facilities:
Principal amount of debt	1,461	1,423
EUR Dollars [Member] | Due in 2024 [Member] | 3.5% Senior Notes [Member]
Senior Secured Credit Facilities:
Principal amount of debt	$ 770	$ 749

Credit Arrangements - Summary61

Credit Arrangements - Summary of Debt (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2018
Senior Secured Term A Loan [Member] | Due in 2021 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,021
Senior Secured Term B Loan [Member] | Due in 2025 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,025
Senior Secured Term B Loan [Member] | Due in 2024 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,024
Senior Secured Term B Loan [Member] | U.S Dollars [Member] | Due in 2025 [Member]
Debt Instrument [Line Items]
Average floating rate	4.30%
5.0% Senior Notes [Member] | Due in 2026 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,026
5.0% Senior Notes [Member] | U.S Dollars [Member] | Due in 2026 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	5.00%
3.25% Senior Notes [Member] | Due in 2025 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,025
3.25% Senior Notes [Member] | EUR Dollars [Member] | Due in 2025 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	3.25%
3.5% Senior Notes [Member] | Due in 2024 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,024
3.5% Senior Notes [Member] | EUR Dollars [Member] | Due in 2024 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	3.50%
2.875% Senior Notes [Member] | Due in 2025 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,025
2.875% Senior Notes [Member] | EUR Dollars [Member] | Due in 2025 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	2.875%
4.875% Senior Notes [Member] | Due in 2023 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,023
4.875% Senior Notes [Member] | U.S Dollars [Member] | Due in 2023 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	4.875%
Receivables Financing Facility [Member] | Due in 2020 [Member]
Debt Instrument [Line Items]
Debt maturity year	2,020
Debt instrument interest rate terms, Description	LIBOR at average floating rate of 2.78%
Revolving credit facility [Member]
Debt Instrument [Line Items]
Debt maturity year	2,021
LIBOR [Member] | Senior Secured Term A Loan [Member] | U.S Dollars [Member] | Due in 2021 [Member]
Debt Instrument [Line Items]
Average floating rate	4.30%
LIBOR [Member] | Senior Secured Term A Loan [Member] | EUR Dollars [Member] | Due in 2021 [Member]
Debt Instrument [Line Items]
Average floating rate	2.00%
LIBOR [Member] | Senior Secured Term B Loan [Member] | U.S Dollars [Member] | Due in 2024 [Member]
Debt Instrument [Line Items]
Average floating rate	4.30%
LIBOR [Member] | Senior Secured Term B Loan [Member] | EUR Dollars [Member] | Due in 2024 [Member]
Debt Instrument [Line Items]
Average floating rate	2.75%
LIBOR [Member] | Receivables Financing Facility [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	1.88%
LIBOR [Member] | Receivables Financing Facility [Member] | Due in 2020 [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	2.78%
LIBOR [Member] | Revolving credit facility [Member]
Debt Instrument [Line Items]
Debt instrument interest rate stated percentage	2.00%
LIBOR [Member] | Revolving credit facility [Member] | U.S Dollars [Member]
Debt Instrument [Line Items]
Average floating rate	3.75%

Credit Arrangements - Contractu

Credit Arrangements - Contractual Maturities of Long-term Debt (Detail) $ in Millions	Mar. 31, 2018USD ($)
Debt Disclosure [Abstract]
Remainder of 2018	$ 78
2,019	104
2,020	379
2,021	1,769
2,022	34
Thereafter	8,124
Long-term debt	$ 10,488

Credit Arrangements - Additiona

Credit Arrangements - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2018USD ($)	Mar. 31, 2018GBP (£)	Mar. 31, 2017USD ($)	Apr. 06, 2018USD ($)	Mar. 31, 2018GBP (£)	Dec. 31, 2017USD ($)
Line Of Credit Facility [Line Items]
Proceeds from revolving credit facility	$ 405,000,000		$ 490,000,000
Repayment of revolving credit facility	300,000,000		$ 865,000,000
Outstanding borrowings	10,488,000,000					$ 10,269,000,000
Revolving credit facility [Member]
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount	1,000,000,000
General Banking Facility [Member]
Line Of Credit Facility [Line Items]
Bank guarantees	4,000,000	£ 3,000,000
Aggregate maximum principal amount	14,000,000				£ 10,000,000
Senior Secured Facilities [Member]
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount	5,685,000,000
Outstanding borrowings	5,319,000,000
Available borrowing capacity	366,000,000
Senior Secured Facilities [Member] | Revolving credit facility [Member]
Line Of Credit Facility [Line Items]
Current borrowing capacity	$ 1,000,000,000
Senior Secured Facilities [Member] | Revolving credit facility [Member] | Subsequent Event [Member]
Line Of Credit Facility [Line Items]
Aggregate maximum principal amount				$ 1,500,000,000

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	Feb. 14, 2018	Mar. 31, 2018	Dec. 31, 2017	Jul. 31, 2015
Class Of Stock [Line Items]
Preferred stock, authorized		1,000,000
Preferred stock, par value		$ 0.01
Preferred stock, shares issued		0	0
Preferred stock, shares outstanding		0	0
Equity repurchase program increase in authorized amount	$ 1,500,000,000
Equity repurchase program authorized amount	$ 5,725,000,000
Repurchase of stock, shares		874,627
Repurchase of stock, value		$ 86,000,000
Equity available for repurchase under the repurchase program		1,600,000,000
Q2 Solutions [Member]
Class Of Stock [Line Items]
Percentage of Quest's non-controlling interest in Q2 Solutions				40.00%
Quest's non-controlling interest in Q2 Solutions		$ 257,000,000
Quest [Member]
Class Of Stock [Line Items]
Ownership percentage				60.00%

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Non-controlling Interests (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Equity [Abstract]
Beginning Balance	$ 249	$ 227
Comprehensive income:
Net income	4	2
Foreign currency adjustments, net of income tax	4
Ending Balance	$ 257	$ 229

Business Combinations - Schedul

Business Combinations - Schedule of Preliminary Allocation of Purchase to Certain Tangible and Intangible Assets Acquired and Goodwill (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Business Acquisition [Line Items]
Total cost of acquisitions, net of cash acquired	$ 20	$ 150
Goodwill	12,041		$ 11,850
Several Individually Immaterial Acquisitions [Member]
Business Acquisition [Line Items]
Total cost of acquisitions, net of cash acquired	31
Goodwill	7
Total intangible assets	25
Several Individually Immaterial Acquisitions [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Total intangible assets	$ 20
Several Individually Immaterial Acquisitions [Member] | Customer Relationships [Member] | Minimum [Member]
Business Acquisition [Line Items]
Amortization Period	8 years
Several Individually Immaterial Acquisitions [Member] | Customer Relationships [Member] | Maximum [Member]
Business Acquisition [Line Items]
Amortization Period	10 years
Several Individually Immaterial Acquisitions [Member] | Non-compete Agreements [Member]
Business Acquisition [Line Items]
Amortization Period	5 years
Total intangible assets	$ 1
Several Individually Immaterial Acquisitions [Member] | Software [Member]
Business Acquisition [Line Items]
Total intangible assets	$ 4
Several Individually Immaterial Acquisitions [Member] | Software [Member] | Minimum [Member]
Business Acquisition [Line Items]
Amortization Period	2 years
Several Individually Immaterial Acquisitions [Member] | Software [Member] | Maximum [Member]
Business Acquisition [Line Items]
Amortization Period	5 years

Business Combinations - Sched67

Business Combinations - Schedule of Preliminary Allocation of Purchase to Certain Tangible and Intangible Assets Acquired and Goodwill (Parenthetical) (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Business Combination Increase Decrease To Reflect Liabilities Acquired At Fair Value [Abstract]
Contingent consideration and deferred purchase payments	$ 11

Restructuring - Additional Info

Restructuring - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Restructuring And Related Activities [Abstract]
Severance and related costs	$ 25
Facility exit costs	$ 1

Restructuring - Summary of Amou

Restructuring - Summary of Amounts Recorded for Restructuring Plans (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	$ 84
Expense, net of reversals	26
Payments	(24)
Foreign currency translation and other	2
Restructuring reserves, ending balance	88
Severance and Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	80
Expense, net of reversals	25
Payments	(23)
Foreign currency translation and other	2
Restructuring reserves, ending balance	84
Exit Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserves, beginning balance	4
Expense, net of reversals	1
Payments	(1)
Restructuring reserves, ending balance	$ 4

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Federal corporate income tax rate	21.00%		35.00%
Effective income tax rate	22.40%	18.90%
Tax benefit related to purchase accounting amortization	$ 47	$ 64
Purchase amortization due to merger	$ 207	$ 182

Employee Benefit Plans - Summar

Employee Benefit Plans - Summary of Components of Net Periodic Benefit Cost for Pension benefits (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Compensation And Retirement Disclosure [Abstract]
Service cost	$ 10	$ 9
Interest cost	5	5
Expected return on plan assets	(11)	(9)
Net periodic benefit cost	$ 4	$ 5

Comprehensive Income - Summary

Comprehensive Income - Summary of Components of AOCI (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	$ 7,995
Ending Balance	8,196
Beginning Balance	219
Other comprehensive income before reclassifications	40
Reclassification adjustments, tax	(1)
Ending Balance	258
Other comprehensive income before reclassifications	204
Reclassification adjustments, net of tax	1
Foreign Currency Translation [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	(214)
Other comprehensive income before reclassifications	163
Ending Balance	(51)
Derivative Instruments [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	14
Other comprehensive income before reclassifications	1
Reclassification adjustments, before tax	2
Ending Balance	17
Defined Benefit Plans [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	30
Ending Balance	30
Accumulated Other Comprehensive (Loss) Income [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning Balance	49
Ending Balance	$ 254

Comprehensive Income - Summar73

Comprehensive Income - Summary of Adjustments for (Gains) Losses Reclassified from AOCI into Condensed Consolidated Statements of Income and Affected Financial Statement Line Item (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	$ 2	$ 2
Income tax benefit	1
Total net of income taxes	1	2
Foreign Exchange Forward Contracts [Member] | Revenues [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	(2)	5
Foreign Exchange Forward Contracts [Member] | Other Expense (Income), Net [Member]
Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items]
Total before income taxes	$ 4	$ (3)

Segments - Additional Informati

Segments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2018Segment
Segment Reporting [Abstract]
Number of reportable segments	3

Segments - Operations by Report

Segments - Operations by Reportable Segments (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Segment Reporting Information [Line Items]
Revenues	$ 2,563	$ 2,360
Costs of revenue, exclusive of depreciation and amortization	1,652	1,526
Selling, general and administrative expenses	420	381
Depreciation and amortization	(282)	(232)
Restructuring costs	(26)	(19)
Income from operations	183	202
Operating Segments [Member]
Segment Reporting Information [Line Items]
Segment profit	552	515
Operating Segments [Member] | Commercial Solutions [Member]
Segment Reporting Information [Line Items]
Revenues	985	863
Costs of revenue, exclusive of depreciation and amortization	547	467
Selling, general and administrative expenses	185	164
Segment profit	253	232
Operating Segments [Member] | Research & Development Solutions [Member]
Segment Reporting Information [Line Items]
Revenues	1,365	1,263
Costs of revenue, exclusive of depreciation and amortization	923	863
Selling, general and administrative expenses	156	136
Segment profit	286	264
Operating Segments [Member] | Integrated Engagement Services [Member]
Segment Reporting Information [Line Items]
Revenues	213	234
Costs of revenue, exclusive of depreciation and amortization	182	196
Selling, general and administrative expenses	18	19
Segment profit	13	19
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Selling, general and administrative expenses	61	62
Segment profit	$ (61)	$ (62)

Earnings Per Share - Summary of

Earnings Per Share - Summary of Weighted-Average Outstanding Stock Based Awards Excluded from Computation of Diluted Earnings Per Share (Detail) - shares shares in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from diluted earnings per share	1.8	1.6
Performance Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from diluted earnings per share	0.7	0.3
Share-Based Awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total shares excluded from diluted earnings per share	1.1	1.3